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ABSTRACT
ROLE OF CIRCULATING ANGIOGENIC STEM CELLS IN
CARDIOVASCULAR DISEASE
Nagma Zafar
November 30, 2015
Circulating angiogenic stem cells (CACs) are rare cells found in peripheral blood
that have been shown to contribute to endothelial repair and new blood vessel
formation. These cells could be biomarkers and/or therapeutic targets for the
assessment and prevention of cardiovascular disease (CVD), which is the
leading cause of mortality globally and in the United States. Diabetes is an
independent risk factor for CVD and its prevalence has been increasing in
epidemic proportions since the mid 1990s. The vascular pathophysiology
associated with diabetes is not completely understood and there are inconsistent
reports on the role of CACs in diabetic vasculopathy. To study this further we
tested the hypothesis that diabetes depletes circulating levels of CACs, due to
hyperglycemia or insulin resistance and that CAC depletion contributes to
vascular dysfunction associated with diabetes. It was further proposed that in
subjects with diabetes CACs have decreased proliferative and angiogenic
potential and that changes in plasma cytokine levels are associated with CAC
levels. Studies presented here identify one subgroup of CAC, (CAC-3:
v

AC133+/CD34+/CD45dim/CD31+/CD14-), that is reduced in diabetes and whose
levels are negatively associated with hyperglycemia and endothelial function.
Furthermore we found that increased plasma levels of soluble ICAM-1 are also
associated with decreased CAC-3 levels and VEGFR2 surface expression. Our
results also show that subjects with diabetes have CACs with decreased
adhesive and proliferative capacity. These studies identify the specific CAC
phenotypes that are affected by diabetes and suggest that CAC levels are a
robust index of long-term glycemic control and that their levels reflect
hyperglycemia rather than insulin levels. These studies also suggest that CAC
levels may be monitored by bedside assessment of endothelial function. Overall
these findings may help in the prognosis and early identification of CVD risk in
patients

with

diabetes,

independent

vi

of

other

risk

estimates.
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CHAPTER I
GENERAL INTRODUCTION
CIRCULATING ANGIOGENIC STEM CELLS IN CARDIOVASCULAR HEALTH
AND DISEASE

Cardiovascular disease (CVD) is the leading cause of mortality in both
men and women not only in the United States but also globally (1). The overall
CVD death rate in 2011 was 31.3% in the United States, with coronary artery
disease being the most prevalent type of heart disease (2). Although the death
rate from CVD has been declining since the mid 1990s the burden of poor
cardiovascular health remains high (3; 4). The economic costs of CVD and stroke
were estimated at $475.3 billion in 2009, which included $313.8 billion in direct
medical expenses and $161.5 billion in indirect costs. (5).
The prevalence of diabetes and obesity, both independent risk factors for
CVD has seen a rapid incline since the mid 1990s. According to the National
Diabetes Surveillance System, a division of the Centers for Disease Control and
Prevention (CDC), USA, the percent of the US adult population with the
diagnosis of diabetes in 1990 was 2.5% or 6.2 million. This number has more
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than tripled in the past two decades to 9.3% or 29.1 million in 2012. If this trend
continues it is projected that by the year 2050, 1 in 3 US adults could have
diabetes. This trend could potentially reverse gains made in decreasing CVD
mortality rates and decrease gains in life expectancy for the next generation for
the first time in 100 years. (6; 7).
Diabetes associated CVD is an expensive and serious cause of morbidity
and mortality (8). The current burden of diabetes in terms of direct and indirect
costs in the United States is around $245 billion. Among adults diagnosed with
diabetes, mortality from all causes is about 2.5 times higher than among adults
without the diagnoses of diabetes. The absolute risk of CVD deaths in diabetics
compared to non-diabetics is higher across every stratum of age, race, and risk
factor level. (9). The cardiovascular complications of diabetes affect both the
macro- and micro-vasculature and include coronary heart disease (CHD), stroke,
peripheral

arterial

disease,

nephropathy,

retinopathy,

neuropathy

and

cardiomyopathy. Atherosclerotic CHD often affects multiple vessels, is
asymptomatic, and patients with diabetes who develop coronary artery disease
have outcomes far worse than those who do not have diabetes (10; 11). Mortality
from stroke is almost 3-fold higher in diabetics than non-diabetics (12). The
leading cause of end stage renal failure, non-traumatic limb amputations and
blindness in adults is diabetes (6). Almost 75% of the mortality in diabetics arises
from CVD (13).
The pathogenesis of CVD in diabetes is poorly understood and further
insight is required to develop interventions, preventive care strategies and
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therapeutics for diabetes-associated vascular pathology. All of the major CVD
risk factors, such as hypertension, hyperlipidemia, obesity, smoking, age,
gender, and genetic factors continue to act as independent contributors to CVD,
with the addition of the metabolic risk factors associated with diabetes (9).
Specific to type 2 diabetes (T2D) is hyperglycemia and hyperinsulinemia that
possibly accelerate vasculopathy by enhanced formation of glycosylated proteins
and advanced glycation products and by increasing endothelial dysfunction (14).
The crucial role of the endothelium, the innermost lining of the
vasculature, has long been apparent in vascular pathology. The endothelium
plays a prominent role in the development of many pathophysiological conditions
such as atherosclerosis, hypertension and thrombosis (15; 16). It also
participates in many homeostatic processes such as control of vasomotor tone,
trafficking of cells and nutrients, maintenance of blood fluidity, permeability
regulation and formation of new blood vessels (17). In its quiescent state, the
endothelium

expresses

an

anticoagulant,

antiadhesive

and

vasodilatory

phenotype. Upon activation, the endothelium has the capacity to perform new
functions without evidence of cell injury. The activated endothelium develops
procoagulant, proadhesive and vasoconstricting properties in response to
physiological and pathophysiological stimuli, with subsequent return to the
quiescent state. The persistence of the activated phenotype results in a
dysfunctional endothelium that is prone to premature apoptosis setting the stage
for vascular disease states (17).
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The endothelium displays several homeostatic imbalances in diabetes.
Insulin signaling in the healthy endothelium is mediated predominantly through
activation of the phosphoinositide-3 kinase (PI3-K)/Akt pathway with minimal
activation of mitogen-activated protein kinase (MAPK) /extracellular signalregulated kinase (ERK) pathway (18; 19). Activation of the PI3-K/Akt enhances
endothelial nitric oxide synthase (eNOS) expression and nitric oxide (NO)
production, which plays multiple roles in preventing atheroma formation (20; 21).
NO diffuses into the surrounding vascular smooth muscle cells and induces
vasodilatation. NO also inhibits platelet aggregation, SMC proliferation and
nuclear transcription of leukocyte-adhesion molecules including vascular cell
adhesion molecule (VCAM) and intercellular adhesion molecule (ICAM) (22). In
normal physiological circumstances, the PI3-K/Akt pathway predominates and
endothelial function is preserved. However while in T2D that is characterized by
insulin resistance there is a selective deficiency of the PI3-K/Akt pathway
resulting in decreased NO (18; 23). Signaling via the MAPK/ERK pathway is
unaffected. Continued activation of MAPK/ERK pathway enhances secretion of a
potent vasoconstrictor endothelin (ET-1), which through its pro-inflammatory and
mitogenic effects augments the pathogenesis of CVD (24; 25).
Endothelial dysfunction in diabetes is also mediated via inflammatory
factors [such as interluekins, C-reactive protein, ICAM, VCAM and tumor
necrosis factor-alpha (TNF-α)] and hyperglycemia [through the receptor for
advanced glycation end-products (RAGE)] by the activation of nuclear factor κB
(NFκB), a transcription factor that further stimulates expression of inflammatory
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genes (26; 27). Overexpression of either TNF-α or IκB kinase stimulates the
development of insulin resistance that ultimately down regulates the PI3-K/Akt
pathway and decreases NO production resulting in endothelial dysfunction (28).
Oxidative stress from the accumulation of reactive oxygen species (ROS)
also decreases NO bioavailability by either direct degradation of NO, through
formation of peroxynitrite or by uncoupling of eNOS (29). In the presence of
insulin resistance peroxynitrite has also been implicated in the down regulation of
PI3-K/Akt pathway (30). In the normal physiological state mitochondrial ROS
production is minimal. However during periods of exposure to high glucose, as in
diabetes there is an increase in the proton gradient within the electron transport
chain that enhances superoxide production and leads to an accumulation of
excessive ROS (31).
While endothelial dysfunction can be viewed as an early marker of CVD,
however there is a significant bench-to-bedside gap with this approach as there
are no convenient blood or bedside tests to assess endothelial function (32). The
observation that precursors of the endothelium can be sampled from peripheral
blood

has

expanded

the

ability

to

assess

early

events

in

vascular

pathophysiology. These precursors known as circulating endothelial progenitor
cells (EPCs) or circulating angiogenic stem cells (CACs) have been reported to
participate in the process of endothelial repair and vasculogenesis (33).
Quantitative and qualitative assessments of these cells may serve as a
biomarker of CVD initiation and progression. Preserving or enhancing the
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number and function of CACs could result in novel approaches to preventive care
and therapeutics in cardiovascular medicine.
Development and Repair of the Vasculature
Survival of the vertebrate embryo depends upon the development of a
system that delivers oxygen and nutrients to, and removes wastes from growing
tissues. This is accomplished by the development of the circulatory and the
hematopoietic systems from the embryonic mesoderm. This process is initiated
when signals from the visceral endoderm pattern the underlying mesoderm (3436). Aggregates of mesodermal cells form blood islands in the extra-embryonic
yolk sac. This phase of development is known as primitive hematopoiesis and
occurs at stage E7.0 to E7.5. Cells within the blood island develop into primitive
blood cells, and the surrounding cells flatten to form the primordial endothelial
cells (37; 38). Coalescence of blood islands leads to the development of a
primitive vascular plexus that subsequently remodels to make mature vascular
plexus.
Definitive hematopoiesis is marked by the generation of multi lineage
hematopoietic stem cells from a small subset of the primordial endothelial cells at
stage E8.25 to E9.5 in the extra embryonic yolk sac and by stage E9.5-10.0 in
the embryonic aorta/gonad/mesonephros region, the fetal liver and the fetal bone
marrow. As blood and endothelial cells develop concomitantly this led to the
suggestion of a common progenitor –the hemangioblast, that gives rise to both
hematopoietic and endothelial cells (39-41) (Fig. 1).
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FIGURE 1. Ontogeny of Circulating Angiogenic Stem Cells
Based on the location of the cells this scheme is divided into three overlapping
components - Embryo, Bone Marrow and Peripheral Blood. The red arrows
delineate the pathway to circulating angiogenic stem cells, beginning in the inner
cell mass of the embryo and culminating in the endothelium. CACs are
mesodermal in origin and differentiate from the hemangioblast, which is also a
precursor of hematopoietic stem cells. CACs may also differentiate further
downstream from the granulocyte and macrophage progenitor.
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In an adult, the bone marrow continues to harbor multi-lineage stem cells
that provide the cellular components of whole blood throughout life. Multi-lineage
stem cells that are capable of reconstituting a sublethally ablated bone marrow
are known to be present in the peripheral circulation since 1987 (42). The
observation that stem cells – endothelial progenitor cells also know as circulating
angiogenic stem cells (CACs) are capable of vascular repair and vasculogenesis
in peripheral blood was first made in 1997 by Asahara et al (43).
The existence of CACs challenged the concept that postnatal vascular
repair occurred only by the proliferation of the local endothelium and that new
blood vessels formation occurred only by sprouting from preexisting vessels
(angiogenesis) (44; 45). It has now been proven that new blood vessels in adults
can be made de novo by recruitment of circulating angiogenic stem cells (CACs)
to areas of hypoxia, where these cells proliferate and assemble into blood
vessels that subsequently anastamose with a preexisting vessel (43) (Fig. 2).
This concept was further verified by bone marrow transplantation of genetically
labeled cells and their subsequent incorporation into the new vasculature
supporting ischemic tissue (46-49). CACs were also found to incorporate in
tumor models of angiogenesis, strengthening the evidence that circulating stem
cells contribute to neovasculogenesis (50). Some studies have measured the
percent contribution of CACs to newly formed blood vessels of ischemic lesions
and have estimated that CACs contribute up to 25% of the endothelial cells
therein (51).
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FIGURE 2. The new paradigm in vascular biology
Circulating Angiogenic Stem Cells transgress from the lumen of the blood vessel
and migrate to sites of hypoxia where they assemble and proliferate making
blood vessels de novo that subsequently anastomose with preexisting
vasculature. CACs also repair the existing vasculature by replacing denuded
endothelium.
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However, studies have also reported absence of bone marrow derived
stem cells in the endothelial layer and tunica media of blood vessels in areas of
angiogenesis in models of ischemia and tumor angiogenesis (52; 53). These and
other studies report the presence of bone marrow derived stem cells in the
adventitia of growing collaterals and suggest that these cells may represent
pericytes, fibroblasts or leucocytes that localize to areas of angiogenesis or
arteriogenesis and support the new vasculature by secreting paracrine factors
such as growth factors, cytokines and proteases (54-57).
The contribution of CACs in the repair of injured endothelium was
confirmed by their identification in denuded endothelium post balloon injury, and
their lining on the vascular surfaces of implanted ventricular assist devices and
dacron grafts (58-60). Taken together these studies affirm a new paradigm in
vascular biology that the formation, repair and maintenance of the vasculature
may be in part dependent upon circulating angiogenic stem cells.
Biology of Ciculating Angiogenic Stem Cells
Precursors

of

CACs

–

hemangioblasts

-

reside

in

specific

microenvironments called niches that are mostly located mostly in the bone
marrow (61-63). The presence of CAC niches at other sites such as: the heart,
vascular tissue and spleen, has also been reported (58; 64-68). These
environments

enable

the

maintenance,

self-renewal,

proliferation

and

differentiation of stem cells. Although each type of stem cell has a unique niche,
in general, a niche contains stem cells, stromal cells and extracellular matrix. It
12

receives neuronal inputs and has blood vessels that bring in systemic signals
and provide a conduit for cell egress. The stromal cells may consist of numerous
cell types that include reticular cells, fibroblasts, macrophages, osteoblasts,
osteoclasts, neuronal cells, adipocytes, and pericytes (69; 70). The interactions
of the stem cells with stromal cells, and the extracellular matrix, and the
bioavailability of stem cell cytokines, enables the preservation of the stem cell
pool for long-term renewal thereby contributing to growth, repair and
maintenance of tissues in the adult.
In the steady state, CAC precursors are maintained in the quiescent or Go
phase of the cell cycle except for a small fraction of stem cells that are in the S or
G2/M phases (71). The interactions between stromal cell derived factor (SDF-1),
secreted by the stromal cells and its receptor CXCR4 is responsible for keeping
the stem cells within the niche in a quiescent state (72; 73). Stem cell factor
(SCF) and its receptor c-kit also play an important role in cycling and
reconstituting the stem cell pool in niches (74). Upon stimulation CAC precursors
undergo asymmetric cell division, self-renewing and releasing progenitor cells
into the circulation (75-77).
A variety of stimuli promote the release of CACs into the blood stream.
The most potent physiologic stimuli is hypoxia (78; 79). Growth factors (vascular
endothelial growth factor, placental growth factor, basic fibroblast growth factor),
cytokines (granulocyte colony stimulating factor, granulocyte monocyte colony
stimulating factor, erythropoietin, stromal cell derived factor-1), elastases,
proteases (matrix metalloproteinase 9), hormones (estrogen) and exercise also
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are reported to stimulate or be critically involved in the mobilization of CACs into
circulation (80-82).
Tissue ischemia induces CAC mobilization through the activation of the
transcription factor, hypoxia-inducible factor-1 (HIF-1), which is a heterodimer
composed of α and β subunits. Whlie HIF-1β is constitutively expressed and HIF1α expression is regulated by cellular oxygen concentration. HIF-1α is rapidly
degraded under normoxic conditions, however degradation is inhibited in the
presence of hypoxia allowing dimerization of the two subunits and binding of the
now active HIF-1 to sites in the nucleus that promote transcription of genes such
as VEGF, SDF-1 and erythropoietin (83; 84). The gradients created by these
factors causes changes in the stromal cell-stem cell interactions and in the
extracellular matrix leading to the egress of CACs into circulation (78; 79).
One well described stromal cell-stem cell interactions in c-kit positive stem
cells that enables mobilization of CACs occurs via a protease, matrixmetalloprotinase-9 (MMP-9). Kit Ligand (KitL) is expressed on the surface
membrane of stromal cells and is cleaved by MMP-9 to release soluble KitL
(sKitL). This sKitL binds to the c-kit receptor on the stem cells and initiates stem
cell cycling, differentiation and mobilization. MMP-9 release is regulated by
VEGF, G-CSF and SDF-1 (85).
The survival of CACs in the peripheral circulation is crucial to enable
repair or formation of new vasculature. As CACs home to environments that are
ischemic or have tissue injury they, like other stem cells must have a high
resistance to oxidative stress. Studies have demonstrated increased levels of
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antioxidant enzymes such as catalase, glutathione peroxidase and manganese
superoxide dismutase (MnSOD) in human CACs (86; 87). Increased sensitivity to
apoptosis and decreased expression of Flk-1 was found to be involved in
decreased CAC counts seen in mice deficient in glutathione peroxidase (GPx-1)
that were subjected to ischemia (88). In humans there is evidence that VEGF
acts via the VEGFR2 to promote CAC survival, proliferation and migration (89).
Inflammation or inflammatory cytokines may reduce CAC survival, increase
apoptosis and reduce angiogenesis (90). Accelerated senescence through
telomerase inactivation is another mechanism that could decrease survival of
CACs. Decreased bioavailability of nitric oxide, increased exposure to reactive
oxygen species, hyperglycemia, high levels of ox-LDL and angiotensin-II have
also been implicated in decreased survival of CACs (90-95).
Attachment to sites of vascular repair or migration to sites of new vessel
formation is dependent on a variety of factors that enable stem cell rolling,
adhesion and transmigration. These include: P-selectin and E-selectin
interactions for rolling (96), VCAM and ICAM interactions with integrins for
adhesion (97), and matrix degrading enzymes (MMP-2, MMP-9, cathepsin,
urokinase) for migration (98-100).
Homing of CACs to sites of repair or ischemia involves the CXCR4/SDF-1
interaction (101-103). In the bone marrow the disruption of this interaction is
required for the egress of CACs into the peripheral circulation. Decreased levels
of SDF-1 accompanied by decreased activation of CXCR4 are required for stem
cell mobilization, while the reverse is required for homing. Hypoxic tissues, as
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generated during exercise up regulate SDF-1 resulting in CAC homing to these
sites and new vessel formation (83; 104).
The coordination of this entire process maintains the pliability of the
vasculature and cardiovascular health. Besides contributing to vascular integrity
CACs have been show to secrete growth factors such as: VEGF-A, VEGF-B,
SDF-1, and insulin-like growth factor-1 (105). The paracrine effect of these
factors enables local angiogenesis by promoting migration and differentiation of
the surrounding mature endothelium. In addition, factors secreted by CACs
stimulate cardiac resident c-kit progenitor cells and mature cardiomyocytes and
promote recovery or remodeling of cardiac tissue post injury (46; 106).
Identification of CACs from Peripheral Blood
CACs have been identified from peripheral blood by two methods: 1)
based on surface antigen expression and 2) based on their ability to adhere,
proliferate and form colonies in vitro. Both methods have yielded multiple
phenotypes of cells that have the ability to contribute to new vessel formation.
Yet neither of these methods can reliably predict the fate of these cells in an in
vivo model. Additionally, it is not known if the phenotypes generated by culture
conditions exist in the blood stream (107).
Selection based on Surface Antigens
In peripheral blood CACs are identified as heterogeneous populations due
to their changing surface antigen profile, as they are in the process of losing
stem cell characteristics and acquiring properties of the local endothelium (108).
This has made it difficult to arrive at a single and uniform definition for a
16

circulating angiogenic stem cell (109-111). The difficulty in converging on a single
unifying definition also arises due to the hierarchal proximity of these cells to
hematopoietic stem cells resulting in commonality of some surface antigens.
Stem cells capable of reconstituting the bone marrow after myeloablative
therapy have been identified from the CD34 positive fraction of peripheral blood,
cord blood and bone marrow. This stem cell pool and the AC133 positive pool
are reported to contain stem cells capable of differentiating into endothelial cells
(112-114). The CD34 antigen, sialomucin is a cell surface glycoprotein is found
on hematopoietic stem cells, angiogenic stem cells and on capillary endothelial
cells (33; 115; 116). Although the function of this antigen is not well
characterized, its expression is used for the immuno-purification of stem cells
and its expression is considered to be one of the characteristics of a CAC despite
the fact that it is also expressed on hematopoietic stem cells and on certain
fractions of the mature endothelium (117).
The

AC133

antigen,

prominin

coexists

on

a

subpopulation

of

hematopoietic stem cells that are bright for CD34 surface expression. AC133
expression is not found on mature endothelial cells, hence the dual expression of
AC133 and CD34 represent CACs and not circulating mature endothelial cells.
AC133 expression is lost from stem cells as they differentiate and commit to a
specific lineage (toward the mature cell type). Hence dual expression of AC133
and CD34 is used to identify early and highly proliferative stem cells compared to
the AC133 low or negative/CD34+ cells (118).
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The

surface

antigens

VEGFR2

and

CD31

are

expressed

on

stem/progenitor and mature endothelial cells. Their coexistence with AC133
defines

a

population

of

stem

cells

capable

of

vasculogenesis.

The

AC133+/VEGFR2+ cells have been found in the neointima of ventricular assist
devices. These cells have also been reported to be rapidly mobilized 6 -12 h
following vascular injury and they have been shown to give rise to endothelial
cells (119; 120). Thus combinations of surface antigens present on stem cells
(CD34, AC133) and endothelial cells (KDR/VEGFR2, CD31) are thought to more
accurately define CACs (121; 122).
CACs may be distinguished further as cells of hematopoietic and
endothelial lineages by the expression of CD45 and CD14. Wherein, cells with a
low (CD45dim) or deficient expression of CD45 (CD45 negative), and negative
for CD14 (CD14 negative) are of endothelial lineage rather than of hematopoietic
origin (123; 124).
Selection based on Cell Culture
The three most commonly described cell culture methods for characterizing
CACs from peripheral blood mononuclear cells are as follows:
1) Colony Forming Assay – Endothelial Cell (CFU-EC or CFU-Hill) (125), wherein
mononuclear cells were initially plated on fibronectin-coated plates, and after 48
h the non-adherent cells were collected and replated again on fibronectin coated
plates. The appearance of clusters or colonies with an endothelial cell phenotype
was noted on days 4-7. These colony counts were reported to correlate to
endothelial function and cardiovascular risk (125). Although these CFU-EC
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express endothelial markers, subsequent analysis revealed that these cells also
express myeloid markers such as CD3. The core of the CFU-EC was made of
angiogenic T cells and monocytes that have acquired an endothelial phenotype
due to a high concentration of endothelial growth factors in the media (126). It
has been convincingly demonstrated that early outgrowth cells are predominantly
of monocytic lineage (127).
2) EPC culture assay (128; 129) – where peripheral mononuclear cells were
plated on gelatin or fibronectin-coated plates and the non-adherent cells were
discarded on day 3, and the culture was continued with the adherent cells.
Colonies that appeared from the adherent cells between days 4–10 were called
early EPCs, and outgrowth cells that appeared after day 14 were referred to as
late EPCs. These early and late EPCs differed in their ability to release
cytokines, as the late EPCs had lower cytokine release. Both phenotypes were
able to incorporate into capillaries. The early and late EPCs isolated by this
method were also reported to have myeloid and hematopoietic markers. It is also
reported that in the early EPCs endothelial gene promoters were silenced (130)
3) Endothelial Colony Forming Cells (ECFC) assay (127; 131) - where peripheral
blood mononuclear cells were plated on collagen-1 coated plates and nonadherent cells were removed on day 2, and the culture was continued with the
adherent cells. Endothelial cells with a high proliferative capacity appeared
between days 14 and 21. These cells differed from those of the above methods
in that they lacked myeloid and hematopoietic cell markers. These outgrowth
cells were capable of forming vascular networks in matrigel.
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Regardless of the methodology used for CAC quantification the conclusion
from numerous studies investigating their role in vascular pathology suggests
that these cells are depleted and/or have defective functional capabilities. To be
applicable in a clinical setting, CAC quantification must be a simple, rapid and
reproducible procedure, making flow cytometry the choice method. However
CAC are rare in peripheral blood, and if only 1 or 2 antigenic markers are used to
identify these cells and increase yield then specificity is lost. While increasing the
number of antigenic markers will increase specificity this leads to a low yield with
higher variability. While the culture methods allow for functional assessment of
CACs, they are more time consuming and the exact origin of the cultured cells is
yet to be identified.
CACs as potential biomarkers of CVD
Leucocyte, neutrophil and lymphocyte counts are used routinely as
cellular biomarkers in the assessment of the etiology of febrile events. The utility
of CACs in CDV risk estimation has been studied extensively as their levels are
reported to vary in acute and chronic CVD. These cells seem to reflect the state
of the underlying vasculature and could hence serve as a biomarker for CVD.
Tabulated below are results from some studies that compared levels of
CACs in subjects with and without CVD and its risk factors (Table 1). The overall
trend is a reduction in the number and function of CACs with aging and presence
of CVD risk factors. Increased levels have been reported during physiological
states such as, the follicular stage of the menstrual cycle and exercise (132;
133), and pathological states such as acute ischemia (134).
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The number of CD34+ cells in peripheral blood under steady state
conditions ranges from 1-5/mm3 or 1000–5000/ml blood (135; 136). It is
estimated that about 80% of CD34+ cells are hematopoietic stem cells, about
15% CACs, and the remainder express antigens for other lineages such as
smooth muscle cells (137). The number of circulating CD34+ cells is very small
compared with the other cellular components. In one cubic millimeter of
peripheral blood there are, ~ 5 x 106 red blood cells, ~ 4-10 x 103 white blood
cells, and ~ 110 x 103 platelets. CACs are subsets of the CD34+ fraction and
hence they are fewer in number. It is estimated that the number of CD34+KDR+
cells in 1ml of whole blood is around 350-750 [or 50-100/ 1 million WBC (0.0050.01%)] and the AC133+CD34+KDR+ subset of cells are 20 fold lower (107).
However due to the non-uniform methodologies used for measuring and
characterizing CAC, and the heterogeneity in their identity, normal values of their
levels in the steady physiological state have not yet been established.
CAC levels have also been reported to be predictive of outcomes such as
all cause mortality, CV mortality and major CV events in subjects with CVD;
atherosclerotic disease progression in subjects with stable CAD (138-140); and
all-cause survival and cumulative cardiovascular event-free survival in subjects
with chronic renal failure on hemodialysis (141; 142). These studies support the
role of CACs as a biomarker for CVD, however they are based in high risk
subjects and have a short term follow up period. Longitudinal studies with long
term follow up, and studies in low risk subjects are required to validate the use of
CAC counts as a biomarker for CVD (143).
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TABLE I. Effect of CVD Risk factors on CAC counts and function
Selected studies that report the effects of CVD risk factors on CAC counts in
human subjects are listed. This table reveals that despite the heterogeneity in
identifying CACs their depletion and decreased function are prominent.
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TABLE 1.
CVD Risk
Factor or
Disease
Age
(43-80 years)
Hyperlipidemia
(TotalCholesterol and
LDL –C)
Hyperlipidemia
TG, TC/HDL-C
ratio, 10 year
FRS
HDL-C

Hypertension

Hypertension

Type 2 Diabetes

Type 2 Diabetes
Smoking

Smoking
Obesity

Sum of risk
factors (age, sex,
HTN, DM,
Smoking,
FH of CAD, LDLC level)
FRS score

Study Cohort (n)

Stable CAD patients
(50)
Diagnosis of
Hypercholesterolaemia
(20) and matched
controls (20). No statin
use
Males (24) with 10 yr
average CVD risk of
20 (FRS range 2-36).
No statins
Males (24) with 10 yr
average CVD risk of
20 (FRS range 2-36).
No statins
Newly diagnosed
untreated subjects with
essential hypertension
(30), age and sex
matched controls
135 consecutive
hospitalized patients
with CVD and 25
controls
Subjects ranging in
their glucose tolerance
from NGT(205),
IGT(43), IFG, new
onset of DM(32) to
>20 years of DM
Subjects with T2D (20)
and age-matched
controls (20)
Smokers (15) and
matched nonsmokers
(14), all healthy.
Healthy (15) and CAD
patients (45)
General population 20
men who met criteria
for obesity and
metabolic syndrome,
and 10 age matched
healthy controls
Healthy (15) and CAD
patients (45)

Males with CVD risk
(45)

Effect on CAC
Number
+

êCD34 /AC133

Effect on
Function

+

Reference

Scheubel,RJ.
2003 (144)
Chen,JZ 2004
(145)

êCACs +ve for DIILDL uptake and Lectin
binding

êProliferation,
migration,
adhesion

êCFU-Hill (no
association with
+
+
CD34 /AC133 cells in
PB)
éCFU-Hill (no
association with
+
+
CD34 /AC133 cells in
PB)
+
+
êCD34 /KDR

-

Pellegatta,F
2005.

-

Pellegatta,F
2005.

-

Pirro,M 2007
(146)

-

Umemura,T
2008 (147)

-

Fadini,GP 2010
(148)

+

+

êCD34 /AC133 /
low
CD45
+

êCD34 and not
+
+
CD34 /KDR in those
with IGT and new
onset DM
êEPC clusters in
culture
low

+

êCD45 /CD34 /
+
CD133
low
+
êCD45 /CD34 /CD
+
+
133 /VGEFR2
+
+
êCD34 /KDR
+

+

+

+

êCD34 /KDR

êCD34 /KDR

êCFU-Hill
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Tepper,OM
2002 (149)
Kondo,T 2004
(150)
êMigration in
CAD patients

Vasa,M 2001
(151)
Westerweel,PE
2008 (152)

êMigration in
CAD patients

Vasa,M 2001
(151)

éSenescence

Hill,JM 2003
(125)

Therapeutic potential of CACs
The potential of CACs in treating conditions such as myocardial ischemia and
peripheral limb ischemia has been investigated ever since these cells were first
reported. In animal models of limb ischemia, CAC biology has been approached
from numerous angles to investigate their effect on vascular regeneration. These
approaches have included the use of injections of freshly isolated CACs, cultureexpanded CACs, genetically modified CACs, and/or use of factors that improve
mobilization, survival or homing of CACs (33; 46; 65; 78; 103; 128; 153-155).
These experiments have demonstrated various levels of incorporation of CACs
into the vascular structures, improvements in tissue function and perfusion, and
reduced scarring.
In humans, initial clinical trials using CAC therapy in ischemic conditions
have shown promising results. The Therapeutic Angiogenesis using Cell
Transplantation (TACT) trial was a randomized trial and the first report on the use
of bone marrow-derived mononuclear cells to treat critical limb ischemia due to
peripheral arterial disease. Intramuscular injection of autologous CACs lead to
significant improvements in leg pain, pain-free walking distance, and reduced
ulcer size, that were maintained for at least 2 years (156). At the three years
follow-up assessment the TACT trial showed significantly lowered amputation
rates in the treatment group (157).
Similar positive outcomes have been reported in the first randomized
study investigating the effects of intracoronary infusion of CACs -The
Transplantation of Progenitor Cells and Regeneration Enhancement in Acute
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Myocardial Infarction (TOPCARE-AMI) trial- that has now published a five year
follow up report (158-160). Improvements in cardiac function included reduced
functional infarct size, improvement of LV ejection fraction, reduced diagnosis of
heart failure and no hospitalization for heart failure.
Currently there are several clinical trials using a variety of CAC
phenotypes with different modes of delivery that mostly demonstrate beneficial
effects in patients with critical ischemia (161-164). Because of the heterogeneity
among these trials, it is difficult to identify which CAC phenotype has the most
benefit for CVD. Furthermore, these trials mostly utilize very high-risk individuals
where it is easier to show benefits. Trials in lower risk populations are required to
confirm benefits of CAC therapy. What has been learned from clinical trials so far
is that CAC therapy is feasible with no reports of unexpected adverse outcomes
such as the possibility of tumor development, calcification of vasculature, or
arrhythmias. Overall the safety profile of CAC therapy is promising.
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PROJECT OBJECTIVE

A dysfunctional endothelium is the primary determinant of many
pathophysiological states especially CVD. Circulating angiogenic stem
cells (CACs) play an important role in maintaining endothelial health and
in new blood vessel formation. Levels of CACs have been found to be
predictive of cardiovascular events and mortality.

Although the levels of

these cells reflect overall CVD risk, studies assessing their association
with major CVD factors such as hypertension, dyslipidemia and diabetes
have yielded inconsistent results and the mechanisms contributing to their
depletion remain unknown.

We hypothesized that CAC depletion in

diabetes is mediated in part by hyperglycemia or insulin resistance and
that this depletion contributes to vascular dysfunction. We further
proposed that in diabetics CACs have decreased proliferative and
angiogenic potential and that altered plasma cytokine levels impact CAC
levels. To test these hypotheses we conducted a cross sectional human
study and addressed the following specific aims 1) quantify phenotypically
distinct circulating levels of angiogenic cells in subjects with and without
diabetes and analyze the association of these cells with diabetes,
hyperglycemia, insulin resistance and endothelial dysfunction (Chapter II);
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2) measure and analyze cellular and plasma factors that contribute to
changes in CAC levels (Chapter III); 3) assess the angiogenic potential of
the cultured CACs from subjects with and without diabetes using in vivo
and in vitro assays (Chapter IV).
We found that CACs expressing surface antigens AC133, AC133/CD31,
CD34,

CD34/CD31,

CD34/KDR,

CD34/AC133/CD45

and

CD34/AC133/CD31/CD45dim are lower in subjects with diabetes.
CD34+/AC133+/CD31+/CD45dim cells (CAC-3) were found to have an
inverse relationship with HbA1c and fasting plasma glucose, but not with
insulin levels or the HOMA-IR score. Peripheral endothelial function was
found to have a strong a positive correlation with CAC-3. In diabetics,
decreased levels of CAC-3 were associated with decreased surface
expression of VEGFR2 and CXCR4 in diabetics and soluble ICAM-1
levels had a negative correlation with CAC-3 counts and VEGFR2
expression. These novel new associations could potentially reduce the
bench-to-bedside gap in assessing early endothelial dysfunction in
subjects with diabetes.
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CHAPTER II
DEPLETION OF CIRCULATING ANGIOGENIC STEM CELLS IN TYPE 2
DIABETES AND ENDOTHELIAL DYSFUNCTION

INTRODUCTION
Cardiovascular mortality is the leading cause of death worldwide (1).
Identifying early and specific indicators of declining vascular health allows
a greater window of opportunity for institution of preventive care measures
that delay progression to the disease state. Among those noncommunicable diseases of enormous economic and clinical significance is
diabetes related CVD. With increasing obesity and other risk factors, the
global prevalence of diabetes is estimated at 8.3% or 387 million
(http://www.idf.org/diabetsatlas/), and in the United States it is estimated to
be at 9.3% or 29.1 million in 2012. Diabetes-associated CVD is an
expensive and serious cause of morbidity and mortality (8). The current
burden of diabetes in terms of direct and indirect costs in the United
States is around $245 billion. Among adults diagnosed with diabetes,
mortality from all causes is about 1.5 times higher than among adults
without the diagnoses of diabetes.
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The role of CACs in diabetes-related vasculopathy has been an area of
intensive research since CACs were first reported in 1997 as endothelial
progenitor cells (EPCs) (43; 107). CACs are heterogeneous populations of stem
cells in peripheral blood that are in the process of loosing their stem cell
characteristics and acquiring properties of the local endothelium (108). They are
defined as cells that have a combination of stem cell surface antigens such as,
CD34, AC133 and endothelial antigens such as KDR/VEGFR2 or CD31 (121;
122). Most studies have reported CACs as cells that express either only CD34 or
CD34/KDR antigens, without accounting for the pan-leukocyte antigen CD45 or
the monocyte antigen CD14. This omission may not adequately discriminate the
hematopoietic stem cells from CACs (123; 124).
The impact of hyperglycemia, prediabetes and overt diabetes on CACs
has been extensively studied (165; 166), more so in relation to CVD outcomes
such as acute myocardial infarction (167-169). Most studies have reported a
depletion of CACs as defined by only CD34 surface antigen or CD34/KDR
expression. Diabetes is also reported to adversely impact all stages of CAC
biology including mobilization, survival, homing and proliferation (170; 171).
Studies reporting the impact of common anti-diabetic medications and related
interventions on CACs (172-174) have also shed some light into this very
complex area of diabetic vascular therapeutics. However there are very few
reports on the association of CAC levels and clinical measures of endothelial
function. One study reported a negative correlation of CAC colony outgrowth
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cells and endothelial function as measured by flow mediated dilation (FMD) of
the brachial artery (125).
Hence we examined the association of CACs with Type 2 Diabetes (T2D)
and indices of glycemic control, CVD risk and with markers and measures of
endothelial function that will help improve effective bench to bedside screening
and intervention in subjects with T2D.
Using

a

comprehensive

CD34+/AC133+/CD31+/CD45dim/CD14-;

definition
CAC-3

we

of

a

hypothesized,

CAC
that

the

depletion of this phenotype occurring in Type 2 Diabetes is mediated in part by
hyperglycemia or insulin resistance and is associated with endothelial
dysfunction. To address this we studied a cohort of subjects with and without
Type 2 Diabetes. Other measurements included peripheral arterial tonometry,
levels of 17 other CAC phenotypes and inflammation and oxidative stress
markers. In this study we assessed only one aspect of endothelial dysfunction
which is reactive hyperemia as measured by change in pulse wave amplitude
following a period of ischemia.
METHODS AND MATERIALS
Study Cohort
The cohort was selected from the University of Louisville Endocrinology
and Primary Care Clinics during the period between June 2011 and May 2013.
Subjects were prescreened and those with conditions known to affect peripheral
blood cell counts and bone marrow function were excluded from the study. These
conditions included malignancies, organ transplant, renal replacement therapy,
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type 1 diabetes, untreated thyroid disease, anemia, acute infections, HIV
infection, hepatitis, and unhealed wounds. Subjects taking hormone replacement
therapy, or medications affecting bone marrow function or peripheral blood cell
counts, those that received transfusion of blood products within the past year, or
hospitalization within past 5 months were also excluded from the study. Other
exclusion criteria included subjects unwilling or unable to provide informed
consent, pregnant or lactating women, prisoners and other vulnerable
populations. Subjects were between the ages of 22 and 65 years. The study was
approved by the Institutional Review Board at the University of Louisville (IRB
10.0350), and all individuals gave a written informed consent. A total of 108
subjects enrolled in the study but in the final analysis 3 subjects were eliminated
due to processing errors with their samples.
Clinical procedures
Subjects enrolling in the study had a morning appointment and were
requested to fast for a minimum of 8 h. All menstruating female subjects were in
the luteal phase of their cycle. At the clinic, subjects filled out a Health and
Diabetes Questionnaire, biometrics were recorded, and urine and venous blood
samples were collected.
Peripheral endothelial function was measured using the EndoPAT,
instrument, according to the guidelines recommended by the manufacturer
(Itamar Medical). The EndoPAT uses fingertip plethysmography to measure the
changes in pulse wave amplitude observed before and after a period of reactive
hyperemia, which is quantified as a score and reported as the Reactive
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Hyperemia Index (RHI). A score of 2.00 or higher indicates good endothelial
function and a score lower than 1.67 indicates poor endothelial function. RHI has
been reported to correlate with flow-mediated dilation of the brachial artery in
subjects with coronary artery disease (CAD) (175). It is also reported to indicate
early endothelial dysfunction in subjects with CAD (176).
Waist and hip was measured in accordance with WHO 2008 Expert
Consultation Report. Body fat percentage was measured using a hand held
bioelectrical impedance instrument (Omron, model BF306) and expressed as a
percent of the body weight.
Circulating Angiogenic Stem Cell Quantification
Eight ml of venous blood was collected in a Mononuclear Cell preparation
tube (CPT: Becton Dickinson) and processed within 4 h of collection.
Mononuclear cells were separated by centrifugation at 1700g for 30 min. The
buffy coat layer was collected and washed twice with PBS+1%BSA. Cells were
pelleted by centrifugation at 400g for 5 min, and incubated with FcR block
(Miltenyi

Biotec)

for

10

min.

Aliquots

of

50ul

were

then

used

for

immunophenotyping. The following fluorescently-tagged anti-human monoclonal
antibodies were incubated mononuclear cells for 30min in the dark: CD41a-FITC
(BD Biosciences), CD235a-FITC (eBioscience), CD16-FITC (eBioscience),
CD14-q655 (Invitrogen), CD34-PE-CF594 (BD Biosciences), AC133-APC
(Miltenyi Biotec), CD31-V450 (BD Biosciences), VEGFR2-Alexa Fluor 700 (R&D
Systems) CD184 (CXCR4)-PE-Cy7 (eBioscience), and CD45-V500 (BD
Biosciences). In addition a live-dead green stain (Invitrogen) was used to
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discriminate cell viability. The cells were washed and re-suspended in
PBS+1%BSA at a cell concentration of 2 million cells/ml. A 50ul aliquot of
counting beads (Accucount; Spherotch) was added and sample then run on an
LSR II (Becton Dickinson) set to acquire 20,000 beads.
Collected events were analyzed using FlowJo software. Initial gating
selected a mononuclear cell population that was negative for CD235a, CD41a,
CD16, CD14 and the dead cell marker, thus removing red blood cells, platelets,
granulocytes and monocytes. This non-monocytic mononuclear population was
then gated for CD31+ and CD45dim cells. Finally, CACs were defined within this
population as those cells positive for CD34 and AC133. Positive gating was
accomplished using an unstained sample from the same subject (Figure 3A and
B). CAC numbers were quantified and normalized to 1 ml of whole blood using
bead counts. Gating strategies for the other CAC phenotypes differed after the
selection of the non-monocytic mononuclear population and are depicted in
Figures 4A and B.
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FIGURE 3. Scheme for sample processing and Gating Strategy for CAC-3
(A). Buffy coat layer from the CPT tube was collected, washed and aliquots used
for surface staining. Scatter plot for the initial gating scheme is depicted, showing
the gates around the lymphocyte (or mononuclear) population and counting
beads.
(B). Representative image of gating strategy used for CAC-3. Selection of the
non-monocytic mononuclear population is used for all CAC and KDR
phenotypes. Subsequent gating for CAC-3 was selected from the CD31+ and
CD45dim population, from where CD34+ followed by AC133+ cells were selected.
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FIGURE 3.
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FIGURE 4. Diagram showing gating strategies for 18 phenotypes of CACs
(A). Flow chart of gating strategy used on 105 subjects. Represented in black
lettering are the initial parent gates. The red lettering represents the 14
phenotypes of CACs that were quantified to study the influence of diabetes on
their circulating levels. The purple lettering describes CAC-3 from figure 3B.
(B). Flow chart of gating strategy used on a subset of 87 subjects where surface
expression of KDR (VEGFR2) was also measured.
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FIGURE 4.
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Quantification of blood and urine analytes
Plasma was separated from EDTA anticoagulated blood by centrifugation
at 1500g for 10 min and stored at -800C until further use. Plasma glucose, insulin
levels, lipid profile, and creatinine were analyzed using the Cobas Mira Chemistry
System (Roche Diagnostic Systems, Inc.). Glucose was measured by the
hexokinase assay (Sekisui Diagnostics, Charlottetown, Canada), insulin by the
immunoturbidimetric assay (Kamiya Biomedical Company, Seattle, WA), and
LDL-C, HDL-C and triglycerides were measured by enzyme assays using
calibrators from Wako Diagnostics (Richmond, VA). Total cholesterol was
measured similarly with calibrators and controls from Thermo Electron.
Creatinine was measured by the Jaffe reaction using alkaline picarate obtained
from Thermo Electron. hsCRP was measured using the VITROS Chemistry
Products at a CLIA certified lab. HbA1c was measured by using the Bayer A1CNow kit according to the instructions by the manufacturer. Complete blood cell
counts were quantified on the Abbott Cell Dyne.
Aliquots of urine samples were frozen at -80oC until further use. Urinary F2
isoprostane metabolite was measured at the Division of Clinical Pharmacology,
Vanderbilt University School of Medicine, Nashville, TN (177).

CVD Risk Score Calculations
Ten-year atherosclerotic cardiovascular disease (ASCVD) risk scores for
heart disease or stroke were calculated using the algorithm published in 2013
ACC/AHA Guideline on the Assessment of Cardiovascular Risk (178)
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The sum of CVD risk factors was calculated by assigning a score of +1 for
each of the following features: age > 40 years, male gender, diagnosis of
hypertension or on medications for hypertension, LDL cholesterol of >130 mg/dl,
current smoker, and diabetes (151).
Measures of Obesity
Three methods were used to account for body size and fat distribution –
body mass index (BMI), waist to hip ratio (WHR) and percent body fat. BMI was
calculated using the standard formula: weight (lb) / [height (in)]2 x 703, with BMI
of ≥ 30 reported as obese. Waist and hip measurements were in accordance with
WHO 2008 Expert Consultation Report (www.who.int). The cut off for high waistto-hip ratio (WHR) was taken from the recommendations in the same report,
where abdominal obesity is defined as a WHR above 0.90 for males and 0.85 for
females. Body fat percentage was measured using a hand held bioelectrical
impedance instrument (Omron, model BF306) and expressed as a percent of the
body weight.
Statistical Analysis
Descriptive statistics are presented as mean ± SD for continuous variables
and as frequencies and percentages for categorical data. Subjects were divided
into high and low CAC count groups using the median value, where cells below
the median value were in the low cell group and cells equal to and above the
median value were in the high cell group. Cohort demographics and CVD risk
factors were compared across the high and low CAC strata using independent
sample t-tests, Wilcoxon rank sum test and chi-squared tests. Continuous
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variables that were not normally distributed were analyzed using the Wilcoxon
rank sum test, a non-parametric test whereas the categorical variables were
analyzed using the chi-squared test. The factors significantly associated with the
cell groups in the univariate analysis were later used in the multivariate analysis.
Logistic regression was used to examine the relationship between CAC-3
levels and diabetes, HbA1c, fasting plasma glucose, HOMA-IR, fasting plasma
insulin, reactive hyperemia index, plasma hsCRP and urinary F2 isoprostane
metabolite independently. Each of the models was adjusted for ethnicity and
body fat percentage.
Furthermore, the association of reactive hyperemia index with CAC-3,
diabetes, HbA1c, fasting plasma glucose, inflammation and oxidative stress was
investigated independently using logistic regression. The reactive hyperemia
index was divided into a low and high group, where a value below two was in the
low group and a value of two and greater was in the high group.
Linear associations between the mean predicted CAC-3 counts and
HbA1c, Fasting Plasma Glucose and Reactive Hyperemia Index were analyzed.
Data management and statistical analyses were performed using SAS 9.4
and IBM SPSS Statistics version 21.0. P values < 0.05 were considered
statistically significant.
RESULTS
Cohort Characteristics

The study population included 105 subjects with a mean age of 48 years.
The cohort was mostly obese with 59% of the cohort having a BMI of 30 or
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greater, and 72% of the cohort having a high waist to hip ratio. There was a
higher but not statistically significant representation of Caucasians (59%) and
females (58%). Self-reported current smokers constituted 20% of the cohort and
13% were reported as former smokers. The diagnosis of hypertension was held
by 52% of the cohort, of T2D by 45%, and of hyperlipidemia by 39%. The mean
HbA1c levels among the diabetics was 8.6% with an average duration of
diabetes of 10 years. The use of metformin, statins and diuretics in the cohort
was 35%, aspirin and ACE Inhibitors use was reported by 31%, and insulin use
by 30% (Table 2).
Association of Diabetes across CAC strata
Cell counts of each of the eighteen phenotypes of CACs measured were
dichotomized into high and low cell groups based on their median value. A chi
square analysis was conducted to test the association of diabetes with the cell
count groups (Table 2.). Subjects with diabetes were predominantly in the low
cell count group with a significant association for six of the eighteen phenotypes
–

CD34+,

CD34+/KDR+,

CD34+/31+,

AC133+,

AC133+/CD31+,

and

CD45+/AC133+/CD34+. The association of CAC-3 with diabetes had a p value of
0.09. However these associations do not account for confounders in the
demographics. CAC-3 was further analyzed in a multivariate logistic regression
model.
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Table 2. Chi square analysis of high and low CAC cell count groups with
Diabetes.
CAC
Phenotypes

Diabetics n (%)
of Total n=105

Diabetics n (%)
in High Count
Group n=52

Diabetics n (%)
in Low Count
Group n=53

P Value

CAC-1
CAC-2
CAC-3
CAC-4
CAC-5
CAC-6
CAC-7
CAC-8
CAC-9
CAC-10
CAC-11
CAC-12
CAC-13
CAC-14
CAC-15
CAC-16
CAC-17
CAC-18

47 (45)
47 (45)
47 (45)
47 (45)
47 (45)
47 (45)
47 (45)
47 (45)
47 (45)
47 (45)
47 (45)
47 (45)
47 (45)
47 (45)
47 (45)
35 (40)
35 (40)
35 (40)

20 (39)
24 (46)
19 (37)
21 (40)
16 (31)
17 (33)
21 (40)
25 (48)
18 (35)
20 (39)
17 (33)
20 (39)
21 (40)
18 (35)
21 (40)
15 (34)
13 (30)
18 (41)

27 (51)
23 (43)
28 (53)
26 (49)
31 (59)
30 (57)
26 (49)
22 (42)
29 (55)
27 (51)
30 (57)
27 (51)
26 (49)
29 (55)
26 (49)
20 (47)
22 (51)
17 (40)

0.198
0.776
0.093
0.372
0.004*
0.014*
0.372
0.499
0.038*
0.198
0.014*
0.198
0.372
0.038*
0.372
0.238
0.040*
0.896

* denotes p < 0.05.
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Demographic comparison across CAC-3 strata
The mean, median and range of CAC-3 counts per ml of blood for the
cohort were 86, 46, and 0 – 919 respectively. The mean ± SD of the low cell
group was 19 ± 13, and of the high cell group was 154 ± 144 per ml blood.
Demographics between the two groups differed only in ethnicity and body fat
percentage, wherein a higher proportion of African Americans were represented
in the high cell group, as were subjects with a higher body fat percentage (Table
3).
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Table 3: Cohort demographics, medical diagnosis and laboratory data
stratified by high and low CAC-3 cell counts.
Variable – n (%) or Mean ± SD
Age (years)
Gender
Female

	
  

Male
Ethnicity
Caucasian

Total
n = 105

High Count
n = 52

Low Count
n = 53

P Value

47.9 ± 10.6

48.2 ± 10.5

47.6 ± 10.8

0.77

61 (58)

	
  

44 (42)
	
  

62 (59)

35 (67)

	
  

17 (33)
	
  

28 (54)

0.06
26 (49)
27 (51)

	
  

	
  
0.02*

34 (64)

African American

31 (30)

21 (40)

10 (19)

Asian

4 (3.8)

0 (0.0)

4 (7.5)

Latino

3 (2.9)

2 (3.8)

1 (1.9)

Others

5 (4.8)

1 (1.9)

4 (7.5)

Caucasian and all others

62 (59)

28 (54)

34 (64)

0.28

African American and all others

31 (30)

21 (40)

10 (19)

0.02*

Diabetes

47 (45)

19 (37)

28 (53)

0.09

Hyperlipidemia

41 (39)

21 (40)

20 (38)

0.78

Hypertension

55 (52)

26 (50)

29 (55)

0.63

Body Mass Index ≥ 30

62 (59)

34 (65)

28 (53)

0.19

High Waist-Hip Ratio

76 (72)

38 (73)

38 (72)

0.75

Body Fat Percentage

34 ± 9

37 ± 8

32 ± 10

0.02*

Current Smokers (self report)

21 (20)

14 (27)

7 (13)

0.08

Former Smokers (self report)

14 (13)

4 (8)

10 (19)

0.09

Never Smokers (self report)

70 (67)

34 (65)

36 (68)

0.78

Insulin

31 (30)

14 (27)

17 (32)

0.56

Metformin

37 (35)

16 (31)

21 (40)

0.34

Statins

37 (35)

19 (37)

18 (34)

0.78

Beta Blockers

23 (22)

13 (25)

10 (19)

0.49

ACE Inhibitors

32 (31)

19 (37)

13 (25)

0.18

Diuretics

37 (35)

16 (31)

21 (40)

0.34

Aspirin

33 (31)

12 (23)

21 (40)

0.07

CVD Risk Factors

Medication
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Table 3: Continued
Total

High Count

Low Count

n = 105

n = 52

n = 53

HbA1c (%)

6.87 ± 2.1

6.71 ± 2.0

7.03 ± 2.2

0.76

Fasting Glucose mg/dl

140 ± 74

136 ± 69

144 ± 80

0.79

Fasting Insulin (µIU/ml)

24 ± 20

24 ± 19

23 ± 22

0.36

HOMA-IR Score†

3.4 ± 3.5

3.4 ± 2.6

3.4 ± 4.3

0.51

Total Cholesterol

191 ± 46

190 ± 45

192 ± 49

0.94

LDL-Cholesterol

103 ± 31

101 ± 28

105 ± 35

0.55

HDL-Cholesterol

48 ± 16

49 ± 19

47 ± 11

0.73

145 ± 129

142 ± 128

149 ± 133

0.76

10 year ASCVD Risk Score

7.7 ± 10.2

8.7 ± 12.0

6.5 ± 7.3

0.72

Sum of CVD Risk Factors

2.7 ± 1.5

2.6 ± 1.4

2.9 ± 1.6

0.31

Plasma Creatinine (mg/dl)

0.98 ± 0.2

0.99 ± 0.2

0.96 ± 0.2

0.74

White Blood Cell Count (K/µL)

5.5 ± 1.9

5.9 ± 2.0

5.2 ± 1.7

0.09

51 (49)

28 (54)

23 (43)

0.33

Variable – n (%) or Mean ± SD

P Value

Glycemic Indices

Fasting plasma lipids (mg/dl)

Triglycerides
CVD Risk Scores

Social and Economic factors
Alcohol Use
Exercise

0.34

None

23 (22)

14 (27)

9 (17)

Mild

35 (33)

18 (35)

17 (32)

Vigorous

47 (45)

20 (39)

27 (51)

Education level ≥ College

79 (75)

37 (71)

42 (79)

0.42

Income ≥ $20,000

60 (57)

28 (54)

32 (60)

0.49

High and low cell count groups were assigned by the median value of the CAC-3
cell count. Abbreviations: HbA1c – Hemoglobin A1c, HOMA-IR – Homeostatic
Model Assessment-Insulin Resistance, LDL – Low Density Lipoprotein, HDL –
High Density Lipoprotein, ASCVD – Atherosclerotic Cardiovascular Disease.
* denotes p < 0.05.

45

Adjusted Associations of CAC-3 levels with Diabetes and Glycemic Indices
In the unadjusted association the diagnosis of diabetes influenced CAC-3
levels at a significance level of less than ten percent (p = 0.09). Also, there was
no significant association between CAC-3 levels and HbA1c, fasting plasma
glucose, fasting plasma insulin levels and HOMA-IR scores. However in the
multivariable analysis, using the logistic regression model (Table 4) and adjusting
for the covariates that were significantly different in the two groups (African
American ethnicity and body fat percentage) diabetes and HbA1c significantly
influenced CAC-3 levels: p = 0.004 and 0.033 respectively. Subjects with
diabetes were 4.4 times more likely to belong to the low CAC-3 group, and with
every unit increase in HbA1c the odds of belonging to the low CAC-3 group
increased by 28%.
Adjusted CAC-3 counts had significant negative correlations with HbA1c
and fasting plasma glucose levels, p = 0.006 and p = 0.004 respectively. This
decrease in cell count was quantified as 6.5%, for every 1 unit increase in HbA1c
and at 6% for every 30 unit increase in plasma glucose level (Figure 5). Fasting
insulin levels and HOMA-IR scores did not influence CAC-3 levels even after
adjusting for known confounders.
Multivariable analysis confirmed the depletion of the 6 phenotypes found
to have significant univariable associations. However these cell types did not
have significant associations with RHI and were hence not analyzed further.
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Table 4: Logistic Regression modeling low CAC-3 count group with each of
the variables listed below.

Variable

P Value

Odds Ratio

95% CI

Diabetes

0.004*

4.407

1.609 – 12.071

HbA1c

0.033*

1.282

1.020 – 1.612

Fasting Plasma Glucose

0.074

-

-

HOMA-IR Score

0.421

-

-

Fasting Plasma Insulin

0.739

-

-

All models are adjusted for African American ethnicity and body fat percentage. *
denotes p < 0.05.
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Figure 5. Linear association between adjusted CAC-3 counts and glycemic
indices. Illustrated are scatter plots of log transformed adjusted CAC-3 counts
against HbA1c (A) and fasting plasma glucose (B).
Plot (A): R2 = 0.077, and for every 1 unit change in HbA1c, cell count decreases
by 6.5%. Plot (B): R2 = 0.095 and for every 30 unit change in plasma glucose,
cell count decreases by 6%.
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FIGURE 5

A.

B.

p = 0.006
β = -0.07
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p = 0.004
β = -0.002

Associations of CAC-3 levels with Endothelial Function, Inflammation and
Oxidative Stress
Endothelial function, as measured by RHI significantly influenced CAC-3
levels in the unadjusted (Table 5) and adjusted analysis (Table 6). In the
adjusted analysis subjects with RHI scores of < 2 were 2.8 times more likely to
belong to the low CAC-3 group. Adjusted CAC-3 counts had a significant positive
correlation with RHI (p = 0.004; Figure 6). The increase in CAC-3 count was
quantified to be 11.25% for every 0.5 unit increase in RHI.
Inflammation as measured by plasma hsCRP, and oxidative stress as
measured by uninary F2 isoprostane metabolite were not significantly associated
with CAC-3 with or without adjustments (Table 5a and 5b).
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Table 5a: Unadjusted association of the independent variables listed below
with high and low CAC-3 count groups.
Variable
n (%) or Mean ± SD

Total

High Count

Low Count

P
Value

Reactive Hyperemia Index

2.1± 0.6

2.3 ± 0.6

2.0 ± 0.7

0.033*

Reactive Hyperemia Index > 2.0

49 (49)

31 (63.3)

18 (36.7)

0.018*

30 (29)

20 (39)

10 (19)

0.15

1.0 ± 0.6

1.0 ± 0.6

0.9 ± 0.6

0.12

Endothelial Function

Inflammation
Plasma hsCRP ≥ 3 mg/L
Oxidative Stress
Urinary F2 Isoprostane
Metabolite ng/mg Cr

* denotes p < 0.05.

Table 5b: Logistic regression modeling low CAC-3 count group with each
of the variables listed below.

Variable

p value

Odds
Ratio

95% CI

Reactive Hyperemia Index < 2.0

0.023*

2.84

1.16 – 6.95

Plasma hsCRP

0.902

-

-

Urinary F2 Isoprostane Metabolite

0.914

-

-

All models are adjusted for African American ethnicity and body fat percentage.
* denotes p < 0.05.
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Figure 6. Linear association between adjusted CAC-3 counts and reactive
hyperemia index (RHI). Scatter plot of log transformed adjusted CAC-3 counts
against RHI: R2 = 0.089 and for every 0.5 unit increase in RHI CAC-3 count
increases by 11.25%.
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FIGURE 6

p = 0.004
β = 0.225
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Associations of Endothelial Function with CAC-3, Diabetes, Glycemic
Indices, Inflammation and Oxidative Stress
Official reference values for RHI are not available, but in general RHI
values below 2 are categorized as endothelial dysfunction, whereas higher RHI
values are considered normal endothelial function (Itamar product information).
To analyze of the influence of the above variables on endothelial function, the
cohort was divided into high and low RHI groups, wherein subjects with a score
greater than two were assigned to the high RHI group. The univariable
associations showed significant associations with CAC-3, diabetes, HbA1c and
fasting glucose levels (Table 6a). Subjects with low CAC-3 counts mostly
belonged to the low RHI group, p = 0.02.

This association persisted in the

multivariable analysis after adjusting for diabetes (Table 6b), wherein subjects
with low CAC-3 counts are 2.5 times more likely to belong to the low RHI group.
The diagnosis of diabetes had a significant negative effect on endothelial
function, p < 0.001. Both HbA1c and fasting glucose levels were negatively
associated with RHI (Figure 7), p = 0.02. For every 1 unit increase in HbA1c, RHI
decreased by 3.4%; and for every 30 unit increase in plasma glucose, RHI
decreased by 3%. Insulin levels, HOMA-IR scores, inflammation and oxidative
stress did not have a significant influence on endothelial function.
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Table 6a: Unadjusted association of CAC-3 count groups, diabetes,
glycemic indices, inflammation, and oxidative stress with high and low
reactive hyperemia groups. High index includes values > 2.

Variable
n (%) or Mean ± SD
CAC-3 Groups
High Count Group
Low Count Group
Diabetes
HbA1c %
Fasting Plasma Glucose
Inflammation
Plasma hsCRP level mg/L
Oxidative Stress
Urinary F2 Isoprostane
Metabolite ng/mg Creatinine
* denotes p < 0.05

Total

High
Index

Low
Index

n=100

n=49

n=51

P
Value
0.02*

51 (51)
49 (49)
44 (44)
6.79 ± 2
138 ± 69

31 (63)
18 (37)
12 (25)
6.36 ± 2
120 ± 55

20 (39)
31 (61)
32 (63)
7.21 ± 2
155 ± 78

<0.001*
0.03*
0.04*

	
   3.5 ± 4.4

	
   3.4 ± 4.3

	
   3.7 ± 4.6

0.88	
  

0.94 ± 0.61 0.88 ± 0.42 0.99 ± 0.74

0.83

Table 6b. Logistic regression modeling low reactive hyperemia group with
the variable listed in each row.

Variable

P value

Odds Ratio

95% CI

Low CAC-3 counts

0.0431*

2.452

1.028 – 5.846

0.0004*
4.938
2.043 - 11.934
Diabetes
Plasma hsCRP
0.653
Urinary F2 Isoprostane
0.593
Metabolite
All models are adjusted for diabetes, and no adjustment is used in the model with
diabetes. * denotes p < 0.05
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Figure 7. Linear association between reactive hyperemia index and
glycemic indices. Illustrated are scatter plots of log transformed reactive
hyperemia index against HbA1c (A), and fasting plasma glucose (B). For plot (A):
R2 = 0.057 and or every 1 unit increase in HbA1c RHI decreases by 3.4%. For
plot (B): R2 = 0.058 and for every 30unit increase in plasma glucose, RHI
decreases by 3%.
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FIGURE 7.

A.

B.

p = 0.016
β = -0.034

p = 0.022
β = -0.001
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DISCUSSION
Cross sectional analysis of this relatively low risk cohort that is mostly
obese, middle aged and contains subjects with the mean duration of diabetes for
ten years reveals that non-monocytic circulating angiogenic stem cells (CAC-3)
are depleted in diabetes. We also observed that other phenotypes (CD34+,
CD34+/KDR+, CD34+/31+, AC133+, AC133+/CD31+, and CD45+/AC133+/CD34+)
were also depleted.
Previous reports of CAC depletion in diabetes compared cell numbers
between diabetic to non-diabetic cohorts. However this is not appropriate as the
two populations are inherently distinct and have many confounders such as
medications (148; 179-181). In this study, the cohort was divided into high and
low CAC count groups, and covariates that were different in the two groups were
accounted for in the multivariate analysis. These covariates were AfricanAmerican ethnicity and body fat percentage. Medication use and disease states
were no different in the two groups. This method confirmed that subjects with
diabetes predominantly had low circulating counts of CACs. A similar analysis
was reported by Werner et al (138) where EPCs were stratified into low, medium
and high groups in subjects that had the diagnosis of CAD by angiography. This
cohort included 507 male patients with a mean age 66 years of which 147 were
diabetics and these diabetics did not have a predilection to the low EPC count
group. However, this study was not designed to assess the influence of diabetes
on EPC levels but to assess the ability of EPCs to predict CVD outcomes in
subjects with CAD.
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Our

data

suggests

that

a

specific

phenotype

of

CAC

(AC133+/CD34+/CD45dim/CD31+/CD14neg: CAC-3) has a linear and negative
correlation with glucose level and a positive correlation with endothelial function.
Identifying specific populations of CACs that are depleted and impact endothelial
function is crucial for the development of therapeutics and in assessing disease
progression. A similar CAC (AC133+/CD34+/CD45dim) population is reported to be
depleted in conditions of CVD risk such as aging, hypertension and smoking
(147; 150) suggesting that these CACs may be useful in monitoring early
vascular dysfunction.
The association of CAC counts and endothelial function found in this study
has not been reported yet, although, Hill et al reported a positive correlation
between FMD and CFU-Hill outgrowth cells in subjects with varying degree of
CVD risk (125). RHI is strongly correlated with FMD and is reported to be low in
subjects with diabetes and has a negative correlation with glucose levels (175;
182; 183). This finding is important in reducing the bench-to-bedside gap in
assessing endothelial function and the reparative capacity of the vasculature.
We were unable to find associations between CAC count groups and
inflammation (hsCRP), and oxidative stress (isoprostane F2 metabolite) in our
cohort. Possible as the population studied is relatively young and has an average
duration of diabetes of 10 years that these effects were not detectable. The
average hsCRP and isoprostane F2 metabolite levels in the cohort are relatively
low at 3.51 mg/L and 1.0 ng/mg creatinine respectively.
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Hyperglycemia could decrease CAC counts by decreasing mobilization of
CACs from the bone marrow, or increasing senescence or apoptosis of CACs.
The vasculature in diabetes is reported to have decreased eNOS and increased
NADPH oxidase activity both effectively decreasing the bioavailability of NO
(184), and signaling through NO is required for the bone marrow release of stem
cells (185). Hyperglycemia enhances senescence of bone marrow cells by via
activation of p38 mitogen activated protein kinase (MAPK) or Akt/p53/p21
pathways (93; 186), and apoptosis via activation of p38 and ERK 1/2 MAPKs
pathways with the activation of nuclear factor (187).
In conclusion we report that both diabetes and endothelial dysfunction
contribute to the depletion of CACs independently. The effect of diabetes on
CAC-3 counts was greater than the effect of endothelial dysfunction on CAC-3
counts (Figure 8a; p = 0.004 and 0.043 respectively). Depletion of CAC-3
correlated with the level of hyperglycemia and the level of endothelial dysfunction
(Figure 8b). This work suggests that CAC counts may be monitored in an office
setting by measuring RHI and that a combination of RHI scores and HbA1c
levels could be indicative of early vascular pathology in diabetes.
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FIGURE 8. Summary of associations between CAC-3, endothelial function
and diabetes.
Illustrated are the adjusted associations of diabetes and low RHI group with low
CAC count group (A), and the association of HbA1c and RHI with CAC counts
(B). Figure (A): The arrowheads point to the dependent (Y) variable. The CAC
model is adjusted for ethnicity and body fat percentage and the Reactive
Hyperemia Model is adjusted for diabetes. Figure (B): Illustrates the association
between CAC counts, HbA1c and RHI; r = Spearman correlation coefficient. Also
depicted are the percent changes in CAC counts and RHI.
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FIGURE 8.
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CHAPTER III
CELLULAR AND PLASMA FACTORS CONTRIBUTING TO CAC-3 DEPLETION
IN DIABETES
INTRODUCTION
In our previous study we found that the circulating levels of CAC-3 were
depleted in subjects with diabetes. Hence, to probe the mechanisms underlying
this depletion, we focused on the role of cellular and plasma factors. Previous
studies have shown that the levels of circulating stem cells in the peripheral
blood depend upon the ability of these cells to proliferate in niches and to be
mobilized and survive in the peripheral blood as well as to home to sites of
endothelial repair or form new blood vessels. Therefore, we examined four key
factors regulating these processes, i.e. the expression of vascular endothelial
growth factor receptor 2 (VEGFR2), C-X-C chemokine receptor type 4 (CXCR4),
and insulin receptor (IR), and mitochondrial membrane potential (ΔΨ).
The VEGF receptors, VEGFR-1, -2 and -3, are a family of receptor
tyrosine kinases that play a key role in angiogenesis and vasculogenesis (188;
189). Of the 3 receptor types, signaling through VEGFR2 has been found to be
most critical for vasculogenesis. The absence of VEGFR2 is embryonic lethal in
knock out mice that die due to the lack of vasculogenesis (190). The receptor is
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mostly expressed on endothelial cells, hematopoietic stem cells, and
megakaryocytes (191; 192). The peptide VEGF-A is the primary ligand for
VEGFR2 although other VEGF isoforms VEGF-C and –D also bind to VEGFR2
as well. Stimulation of VEGFR2 by VEGF-A has been studied extensively in
endothelial cells where it is known to mediate endothelial proliferation, survival,
migration, tubular morphogenesis and sprouting (193; 194). Inhibition of VEGF
signaling leads to capillary regression (195). VEGF has also been found to play
an important role in mobilizing CACs during ischemia (134; 196). In subjects with
T2D early outgrowth cells from peripheral mononuclear cells (CFU-Hill) were
characterized as having decreased proliferation capacity, reduced adhesiveness
and reduced tube-forming capacity in vitro (197). However whether signaling
through VEGFR2 plays a role in these functions and indeed even VEGFR2
density on CAC-3 have not been studied.
CXCR4 is a G-protein coupled receptor that is expressed in several
tissues including hematopoietic stem cells, lymphocytes and endothelial cells.
During embryonic development, interactions of CXCR4 with its ligand SDF-1 is
important for the formation of vascular, hematopoietic, cardiac, and nervous
systems (198; 199). In adults, this interaction is vital for leucocyte trafficking, and
the mobilization and homing of hematopoietic stem cells (200; 201). The
activation and down-regulation of CXCR4 are important for the release and
homing of stem cells (79). A number of growth factors, inflammatory mediators,
and cytokines influence the transcription and expression of CXCR4 (202-204).
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Thus we analyzed the expression of CXCR4 on CAC-3 and its associations with
hyperglycemia, inflammation and oxidative stress.
In addition to VEGFR2 and CXCR4, we also studied the insulin receptor,
which is a receptor tyrosine kinase that mediates the biological effects of insulin
and whose activation on healthy endothelial cells is coupled with the release of
nitric oxide. Extensive evidence suggests that abnormalities in insulin receptor
signaling are critical events underlying the development of T2D (205; 206).
Individuals with insulin resistance have reduced expression of the insulin
receptor in peripheral tissues, particularly the liver, muscle, and adipose tissues
(207). Insulin receptor abundance is an important determinant of the specificity of
insulin action (208). Hence we quantified the expression of insulin receptor on
CAC-3 and its associations with hyperglycemia, inflammation and oxidative
stress.
Hyperglycemia in diabetes negatively impacts tissue function through
several well described mechanisms. These include: (1) increased flux of glucose
and other sugars through the polyol pathway; (2) increased intracellular formation
of advanced glycation end products (AGEs); (3) increased expression of the
receptor for AGEs and its activating ligands; (4) activation of protein kinase C
(PKC) isoforms; and (5) enhanced signaling through the hexosamine pathway
(209). It has been proposed all of these mechanisms are secondary to a single
upstream event the mitochondrial overproduction of reactive oxygen species
(ROS) (210). Several studies have reported the association of mitochondrial
membrane potential (ΔΨ) with ROS production, wherein an increase or decrease
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in ΔΨ is associated with increased ROS production (211-215). During periods of
high glucose concentrations, as in diabetes there is an increase in the proton
gradient within the electron transport chain that enhances superoxide production
and leads to an accumulation of excessive ROS (31). To determine whether
diabetes affects mitochondrial function in CACs we measured change in ΔΨ as
an index of the overall metabolic activity, using a flow cytometry method
developed in our laboratory.
Cytokines

regulate

immune

responses,

hematopoiesis,

and

the

differentiation, migration, activation and proliferation of a variety of cell types
(216). Changes in cytokine profiles from the healthy to the disease state could be
considered as potential surrogates of disease activity. Thus we measured
plasma levels of eighteen cytokines and analyzed their associations with the
diabetes and CAC-3.
METHODS AND MATERIALS
Flow cytometric analysis of receptor density on CAC-3
Mononuclear cells from peripheral blood were processed and stained with
fluorescently tagged anti-human monoclonal antibodies using methods described
in Chapter II. The antibodies used here were AlexaFluor 700 anti-VEGFR2 (KDR;
R&D Systems), PE-Cy7 anti-CXCR4 (CD184; eBioscience) and PE anti-Insulin
Receptor (IR or CD220; eBioscience). Gating strategy for CAC-3 was applied as
also described in Chapter II, and the median fluorescence intensity from each
sample calculated using LSR II (Becton Dickinson) software FacsDiva and
expressed in arbitrary units.
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Flow cytometric analysis of ΔΨ in circulating cells
Initial sample collection, preparation and processing were similar to that
described in Chapter II. For incubation with FcR block, and all subsequent steps,
cells were re-suspended in a solution containing Dulbecco’s Modified Eagle’s
Medium Base (DMEM; Sigma Aldrich D 5030) and 1%BSA. After staining for
CAC surface antigen stains, the cells were washed and incubated with 50nM
tetramethylrhodamine methyl ester perchlorate (TMRM; Sigma Aldridge T 5428)
to assess ΔΨ. Three separate tubes at a cell concentration of 2 x 106 /ml were
used. One of the tubes contained TMRM only, the second tube contained TMRM
and 1µg/ml Oligomycin A (Sigma Aldridge 75351) to measure the maximum ΔΨ
(TMRM max), and the third tube contained TMRM and 1µM carbonyl cyanide 4(trifluoromethoxy)phenylhydrazone (FCCP; Sigma Aldrich C2920) to measure the
basal or background TMRM fluorescence (TMRM min). These tubes were
incubated for 20 min in the dark at 370C, 50ul of counting beads (Accucount;
Spherotch) were added and sample then analyzed on an LSR II (Becton
Dickinson) set to acquire 20,000 beads.
Gating strategies for the collected events were according to the procedure
described in Chapter II. In the final CAC-3 gate, the median fluorescence
intensity of TMRM in the three tubes was determined and the percent maximum
TMRM intensity (% Max TMRM) was calculated using the formula [(TMRM only
– TMRM min) / (TMRM max– TMRM min)] x 100.
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Quantification of Cytokines
Cytokines were quantified using a subset of 87 enrolled subjects. Eight ml
of venous blood was collected in a mononuclear cell preparation tube (CPT:
Becton Dickinson) and processed within 4 h of collection. Plasma was separated
by centrifugation at 1700g for 30 min and aliquots were stored at -80oC until
further use.
Premixed Magnetic Luminex multiplex kits (R&D Systems) were used to
quantify cytokines in three panels: (1) A six plex human angiogenesis panel
(FCSTM02-06) measuring angiogenin, angiopoietin-1, FGF- basic, PDGF-BB,
VEGF-A and VEGF-D; (2) a 10 plex screening panel (LXSAHM-10) measuring
angiopoietin-2, EGF, EPO, HGF, ICAM-1, PlGF, SCF, E-Selectin, VCAM-1, and
VEGF-C; (3) human MMP performance assay (FCSTM07-02) measuring MMP-2
and MMP-9. Only one freeze thaw cycle of the plasma was allowed and samples
were analyzed in duplicate. Procedures were performed according to the
manufacturer's instructions and quantified using the Luminex MAGPIX® CCD
Imager. Concentrations were interpolated from a standard curve generated by
log-transformed values of recombinant human proteins and their respective
median fluorescent intensities. Seven subjects did not have duplicate values and
were eliminated from further analysis.
In brief, the principle of this assay is similar to an ELISA wherein analytespecific antibodies are pre-coated onto color-coded magnetic microparticles.
Standards and samples are pipetted into wells where the immobilized antibodies
bind the analytes of interest. After washing away any unbound substances, a
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biotinylated antibody cocktail specific to the analytes of interest is added to each
well. Following a wash to remove any unbound biotinylated antibody,
streptavidin-phycoerythrin conjugate (Streptavidin-PE), which binds to the
biotinylated antibody, is added to each well. A final wash removes unbound
Streptavidin-PE, the microparticles are resuspended in buffer and fluorescence
analyzed using the Luminex MAGPIX Analyzer. A magnet in the analyzer
captures and holds the superparamagnetic microparticles in a monolayer. Two
spectrally distinct Light Emitting Diodes (LEDs) illuminate the beads. One LED
identifies the analyte that is being detected and the second LED determines the
magnitude of the PE-derived signal, which is in direct proportion to the amount of
analyte bound.

STATISTICS
Analysis of receptor density and ΔΨ
Data are reported as mean ± SEM, and groups were compared using the
non-parametric Mann Whitney test and ANOVA. Linear regression was used to
examine the relationship between receptor expression and HbA1c, hsCRP, and
urinary isoprostane F2 metabolite.
Cytokine analysis
Cytokine values are reported as mean ± SD. As the data had extreme
values it was transformed via winsorisation, a transformation method used for
limiting extreme values to reduce the effect of possibly spurious outliers.
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The heat maps shown in Figure 11 are based on log transformed data,
where the values ranging from low to high are color coded from red to blue
respectively. They represent the data in a visual format, where the Y-axis
represents the cytokine measured and the X-axis represents individual samples.
The association between diabetes and cytokine levels was examined
using the Chi-squared test or the Fishers exact test. Cytokine levels were
dichotomized based on the median split where cytokines below the median value
were in the low cytokine level group and cytokines equal to and above the
median value were in the high cytokine level group. Linear regression was used
to analyze continuous associations. A generalized linear model was used to
confirm the association between soluble adhesion molecules with CAC-3 levels,
after adjusting for covariates that were significantly different in the 2 groups ethnicity, body fat and diabetes.
All data management and statistical analyses were performed using SAS
9.4 and IBM SPSS Statistics version 21.0. P values < 0.05 were considered
statistically significant.
RESULTS
Influence of Diabetes on VEGFR2, CXCR4 and IR expression on CAC-3
As CAC-3 counts were decreased in diabetics, we investigated the
properties of this cell type further to delineate possible causal factors for its
depletion. We measured the surface density of VEGFR2, CXCR4 and IR on
CAC-3 and found that the expression of IR was not different between diabetics
and non-diabetics. However in comparison with non-diabetics the expression of
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VEGFR2 and CXCR4 was significantly lower in diabetics (p = 0.033 and 0.001
respectively; Figure 9A). Of the three receptors studied only the expression of
VEGFR2 had a significant negative correlation with HbA1c, hsCRP and
isoprostane F2 metabolite (Figure 9B).
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FIGURE 9. VEGFR2, CXCR4 and IR expression in non-diabetics and
diabetics. (A) Illustrated are the expression levels of VEGFR2, CXCR4, and IR
in diabetics, and non-diabetics. (B) Illustrated are regression plots demonstrating
the negative associations of VEGFR2 with HbA1c, hsCRP and urinary
isoprostane F2 metabolite.
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Mitochondrial membrane potential in circulating mononuclear cells
Next we measured ΔΨ as an indicator of the proton gradient in circulating
cells. Cell populations lacking stem cell markers (mature + stem cells) had a
higher ΔΨ than stem cells, and CAC-3, the most primitive cell type analyzed, had
the lowest ΔΨ. This observation parallels the metabolic requirements during cell
maturation where the energy currency for stem cells is mostly derived through
glycolysis, while mature cells predominantly use mitochondrial respiration, and
indicating an increase in mitochondrial biogenesis with differentiation and
acquisition of the mature phenotype.
We found no difference in the ΔΨ measured in CAC-3 from diabetics and
non-diabetics despite the increased plasma glucose level in the former group.
However, the ΔΨ in stem cells negative for AC133 (CAC 7), which have been
suggested to be more mature than CAC-3, was significantly higher in diabetics
than non-diabetics (118).
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FIGURE 10. Mitochondrial membrane potential in circulating mononuclear
cells. Illustrated is the % Max TMRM staining (mitochondrial membrane
potential) for various cell populations as determined by FACS in diabetics and
non-diabetics.
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FIGURE 10.
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Plasma analytes levels in diabetics and non-diabetics
We next measured plasma analytes. Listed in Table 7 are our determined
values (R&D Systems) and defined reference values. Our measured values are
within these reported reference values. We then generated heat maps of plasma
analyte levels from the cohort (Figure 11).

Subjects were classified by the

diagnosis of diabetes and graded for changes in cytokine levels by color where
low is red and high is blue. Plasma analyte variations were more apparent in
diabetics than non-diabetics
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Table 7. Levels of plasma analytes measured in the cohort with reference
ranges.

Plasma Analytes
(References for
published values)
Angiogenin ng/ml (217)
Angiopoietin-1 pg/ml (218)
Angiopoietin-2 ng/ml (218)
VEGF-A pg/ml (217)
VEGF-C pg/ml (219)
VEGF-D ng/ml (220)
PLGF pg/ml (221)
SCF pg/ml (222)
EGF pg/ml (223)
PDGF-BB pg/ml (224)
bFGF ng/ml (225)
HGF pg/ml (226)
EPO mIU/ml (227)
sE-selectin ng/ml (228)
sVCAM-1ng/ml (177)
sICAM-1 ng/ml (177)
MMP-2 ng/ml (177)
MMP-9 ng/ml (177)

Measured Level
(Citrate, platelet
poor plasma)
Mean
SD
121
16
615
190
3.3
1.7
14.7
3.4
103
48
223
16
3.4
1.2
51
15
2.2
1.1
44
21
123
12
65
25
1.1
0.11
26
10
581
01
194
83
198
59
18
8

Reference value range
(single plex R&D)
EDTA

1.1-4.4
ND-115
185-1231
ND-437

Non-standard abbreviations: ND = not detected.
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Heparin

Citrate
160-370
39-20,000

1-5
ND-55
222-819
134-508
ND-17
629-1187
ND-11

ND-129
ND-15

ND-32
251-742

3.1-15
13-51
341-897
100-307
141-278

301-875
106-337
155-342
13-105

FIGURE 11. Heat map of levels analytes from plasma of diabetics and nondiabetics. Illustrated are log transformed plasma analyte levels measured from
each subject, where the values ranging from low to high are color coded from red
to blue respectively. Data are represented in a visual format where the analytes
are on the Y-axis and cohort subjects are on the X-axis: (A) non-diabetics, and
(B) diabetics.
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FIGURE 11.
A. Heat map of levels of analytes from plasma of non-diabetics
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B. Heat map of levels of analytes from plasma of diabetics
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Plasma analytes are elevated in diabetics
Each measured analyte was stratified into high and low level groups as
determined by its median value. The association of all anayte level groups with
diabetes was analyzed by chi square analysis and it was found that most
cytokines were higher in diabetics than non-diabetics. Those that were
significantly associated with diabetes include growth factors (Ang-1, Ang-2,
VEGF-A, PlGF, HGF, EPO), inflammatory markers (sICAM-1, sE-selectin) and a
protease (MMP-9; Table 8).
Diabetes-associated analytes were then analyzed for their association
with HbA1c levels. All cytokines except Epo and MMP-9 had a significant positive
correlation with HbA1c (Table 9). As HbA1c levels were associated with low
CAC-3 counts (Chapter II), we next analyzed the association of these cytokines
with this cell type (Table 10). Amongst these cytokines only sICAM-1 levels had a
significant negative correlation with CAC-3 counts (Figure 12).
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Table 8. Significant associations of plasma analytes groups with diabetes,
dichotomized by their median value into high and low groups.
Plasma Analytes

Total n = 80
Diabetics n (%)

Angiopoietin-1
Angiopoietin-2
VEGF-A
PlGF
EPO
HGF
sICAM-1
sE-selectin
MMP-9

High Analyte
Level
Diabetics n (%)

30 (38)
30 (38)
30 (37.5)
30 (37.5)
30 (37.5)
30 (37.5)
30 (37.5)
30 (37.5)
30 (37.5)

Low Analyte
Level
Diabetics n (%)

20 (50.0)
21 (52.5)
24 (60.0)
21 (51.2)
23 (47.9)
26 (65.0)
21 (52.5)
22 (55.0)
19 (47.5)

P Value

10 (25.0)
9 (22.5)
6 (15.0)
9 (23.1)
7 (21.9)
4 (10.0)
9 (22.5)
8 (20.0)
11 (27.5)

0.021
0.006
<.001
0.009
0.018
<.001
0.006
0.001
0.065

P Values are calculated based on Fishers Exact test.

Table 9. Linear regression of HbA1c levels with plasma analytes that had a
significant association with diabetes.

Plasma Analytes
Angiopoietin-1
Angiopoietin-2
VEGF-A
PlGF
EPO
HGF
sICAM-1
sE-selectin
MMP-9

Beta
0.003
0.421
0.263
0.723
2.394
0.044
0.007
0.096
0.051

R square
0.089
0.117
0.195
0.194
0.017
0.304
0.079
0.211
0.037

* denotes p < 0.05.
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P Value
0.007*
0.002*
<.001*
<.001*
0.243
<.001*
0.011*
<.001*
0.085

Table 10. Linear regression of CAC-3 counts with plasma analytes that had
a significant association with HbA1c.
Plasma Analytes
Angiopoietin-1
Angiopoietin-2
VEGF-A
PlGF
HGF
sICAM-1
sE-selectin

Beta
0.057
-2.502
1.528
-8.990
-0.069
-0.275
-0.201

R square
0.014
0.002
0.003
0.014
0.000
0.060
0.000

* denotes p < 0.05.
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P Value
0.303
0.695
0.620
0.289
0.868
0.028*
0.852

FIGURE 12. Association of CAC-3 counts with sICAM-1 levels. Illustrated is
the linear, negative association between sICAM-1 levels and CAC-3 counts.
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FIGURE 12.

p = 0.028
R2 = 0.06
β = -0.28
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High sICAM-1 levels are associated with decreased CAC-3 counts and
decreased expression of VEGFR2 on CAC-3.
As soluble adhesion molecules are a measure of endothelial activation we
expanded our analysis to include sICAM-1, sVCAM-1 and sE-selectin. The
plasma levels of these molecules in the high and low CAC-3 count groups were
different in the univariable analysis (Table 11a). For the multivariate analysis
using generalized linear model, the model was adjusted for confounders that
were previously identified in the cohort in Chapter II (African American ethnicity
and body fat percentage, diabetes). We found that only sICAM-1 levels had a
significant negative association with CAC-3 counts (Table 11b). The association
of sICAM with CAC-9 and CAC-11 was also analyzed and found not to be
significant, suggesting specificity for CAC-3 (data not shown).
sICAM-1 levels had a positive correlation with HbA1c and a negative
correlation with VEGFR2 expression on CAC-3 suggesting that hyperglycemia
induced endothelial activation may play a role in the depletion of CACs in
diabetes (Figure13).
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Table 11a. Unadjusted association between CAC-3 count groups and the
levels of soluble adhesion molecules.

Variables
sICAM-1 ng/ml
sVCAM-1 ng/ml
sE-selectin ng/ml

Total
(n=80)
194 ± 83
581 ± 201
26 ± 10

High CAC-3
Count Group
(n=40)
176 ± 81
567 ± 209
26 ± 10

Low CAC-3
Count Group
(n=40)
211 ± 82
595 ± 195
25 ± 10

P Value
0.056
0.389
0.470

Table 11b. Multivariable analysis using generalized linear models for CAC-3
counts and the independent variable in each row.
Variable
sICAM-1
sVCAM-1
sE-selectin

P Value
0.008*
0.743
0.297

Beta Estimate
-0.0033
0.0002
-0.0129

95% Confidence Limits
-0.0058 - -0.0009
-0.0009 – 0.0013
-0.0113 – 0.0113

Models are adjusted for African American ethnicity, body fat percentage and
diabetes. * denotes p < 0.05.
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FIGURE 13. Association of sICAM-1 with HbA1c and VEGFR2 expression
on CAC-3. Illustrated are the relationships between sICAM-1 and HbA1c (A),
and VEGFR2 (B). While HbA1c increases as sICAM-1 levels increase, VEGFR2,
decreases as sICAM-1 increases.
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FIGURE 13.

A.

B.
p = 0.011
R2 = 0.08
β = 11.52
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p = 0.036
R2 = 0.06
β = -0.10

DISCUSSION
The experiments described in this Chapter investigated the possible
mechanisms by which hyperglycemia could play a role in decreasing CAC-3
counts. We found that the expression of VEGFR2 and CXCR4 on CAC-3 is
diminished in diabetics. It is known that transcription factor HIF and the peptide
VEGF-A upregulate VEGFR2 expression (229). In our cohort despite higher
levels of VEGF-A in diabetics VEGFR2 expression was decreased. Furthermore
we also found that HbA1c, hsCRP and isoprstane F2 metabolite had negative
correlations

with

VEGFR2

expression,

suggesting

that

hyperglycemia,

inflammation and oxidative stress may play a role in the regulation of VEGFR2
expression or they may alter the activity of VEGF-A resulting in decreased
expression of VEGFR2. It is known that the survival, proliferation, and migration
of CACs is influenced by downstream signaling through VEGFR2, and its
decreased expression in diabetics may have contributed to the depletion of CAC3 (230-232).
CXCR4 signaling plays a prominent role in homing of CACs, and its
expression is positively regulated by the transcription factor NRF-1. Several
signaling molecules, cytokines and growth factors including VEGF-A are also
reported to enhance CXCR4 expression, while inflammatory factors attenuate
CXCR4 expression (203; 204; 233; 234). Our finding of decreased CXCR4
expression suggests that decreased mobilization also contributes to CAC-3
depletion, despite the presence of higher levels of growth factors in diabetics.
Reduced mobilization of CACs has been proposed by others as a possible
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causative mechanism for low CAC counts in peripheral blood (78; 235). A
reduction in CXCR4 expression on peripheral blood mononuclear cells has also
been reported in patients with CVD (236; 237). Yet another study reported a
positive correlation of CXCR4 expression on CACs with levels of progenitor cells
in control individuals, while this correlation was absent in diabetic patients (181).
The reduced expression of key surface antigens involved in vascular health in
diabetics directs us to further investigate the regulation of expression of these
antigens, and this may improve our understanding of CAC biology and in the
development of novel therapeutics.
We were unable to detect a difference in ΔΨ in CAC-3, suggesting that the
presence of increased substrate and diabetes does not affect mitochondrial
activity in early circulating stem cells. However, hyperglycemia has been reported
to increase ΔΨ in mature non-insulin sensitive tissues such as kidney and retinal
cells of STZ diabetic rats (238; 239). Other studies have reported an increase in
uncoupling protein 2 in cells exposed to hyperglycemia and postulated this to be
an adaptation to the high ΔΨ to protect against resulting increased ROS
generation (240). A wider array of tests will be necessary to clearly detect and
define the mitochondrial changes in CAC-3 in diabetics.
Increase in ΔΨ in diabetics was detected in slightly more mature
circulating stem cell, CAC 7, whose cell levels were not affected by diabetes.
This suggests that mitochondrial effects of diabetes may be apparent in more
mature CACs, and that changes in cellular function may not manifest with a
corresponding decrease in cell number. Several studies report changes in
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mitochondrial function, number, biogenesis and dynamics in mature insulin
sensitive and non-insulin sensitive tissues (241-244).
Cytokine analysis revealed that most growth factors are increased in
diabetics, and despite this increase CAC counts tend to be lower. Our studies
suggest that decreased expression of receptors on CACs precedes the decline in
growth factors that reported in diabetes of longer duration. Among the
inflammatory analytes measured in plasma, only high sICAM-1 levels were
associated with low CAC-3 counts and with decreased expression of VEGFR2,
suggesting a role for inflammation in the regulation of VEGFR2 expression. The
increase in sICAM-1 was also positively associated with glycemic control. An
inverse correlation of sICAM-1 levels has been reported with CD133+/CD34+
cells in subjects with early ischemic stroke (245). High levels of sICAM-1 are also
reported to be predictive of myocardial infarction in healthy men (246).
Investigating he role of sICAM-1 in T2D, paticularly in the regulation of VEGFR2
expression on CACs could improve our understanding of diabetic vasculopathy.
A summary of our analysis thus far is illustrated in Figure 14. Low CAC-3
counts are associated with diabetes, hyperglycemia, endothelial dysfunction and
high sICAM-1 levels. This suggests that hyperglycemia-induced endothelial
activation leads to an increase in inflammatory factors that negatively impact
CAC-3 levels. Although both diabetes and high sICAM-1 were associated with
decreased expression of VEGFR2 we found no direct association between
VEGFR2 and CAC-3 counts.
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FIGURE 14. Scheme representing the conclusions of Chapter II and III. Low
CAC-3 counts are associated diabetes, hyperglycemia, endothelial function and
high sICAM-1 levels.

94

FIGURE 14.

High,sICAM@1,
Levels,

Low,CAC,3,Counts,

Low,VEGFR2,,
expression,,
on,CAC,3,

Diabetes,
Hyperglycemia,

Endothelial,
,Dysfunc<on,

95

CHAPTER IV
ANGIOGENIC POTENTIAL OF CULTURED CACs
INTRODUCTION
CACs play an important role in the maintenance, and repair of existing
blood vessels and in the formation of new blood vessels. Thus autologous CAC
therapy could have potential for treating vascular disorders. However subjects
with vascular disease are reported to have decreased number and function of
CACs (235; 247; 248). These defects could be overcome by enhancing bone
marrow mobilization of CACs, or by ex-vivo expansion of CACs with or without
modifications to enhance their functionality. Several clinical trials have
demonstrated that such therapy is feasible, does not cause harm and has
potential benefits (156-158; 160). However several aspects such as the mode of
delivery of CACs, number of CACs needed for revascularizations, the ability of
CACs to survive and engraft in ischemic zones, need to be addressed prior to the
use of CACs for regenerative cardiovascular therapy.
Although there have been significant advancements in understanding
CAC biology, the phenotypic identity of the CAC subpopulations that are critical
for

vascular

regeneration

remains

unclear.

96

There

is

also

uncertainty

about the origin of cultured CACs and whether these cultured cells are
functionally identical to those in found circulation (249). Identifying a CAC
precursor that can be easily cultured and is also involved in vascular
regeneration could help in advancing the diagnostic and therapeutic potential of
CACs.
Several methodologies have been reported for ex-vivo expansion of CACs
of which the 3 most common ones are described in Chapter I. CACs may have
different properties and function depending upon culture conditions (250). The
current consensus is that there are two types of outgrowths: the early and late
outgrowths.
The early outgrowth cells or CFU-Hill appear as clusters with central
rounded cells surrounded by spindle shaped cells. The number of clusters are
quantified as colony counts. These colony counts have been shown to correlate
with CVD risk and cells from these colonies improve revascularization in animal
models of ischemia but do not form tube like structures in vitro (33; 128; 251).
They express both myeloid and endothelial markers and it is proposed they
promote vasculogenesis in a paracrine manner by secreting angiogenic factors
(127; 252-254).
Late outgrowth cells have a morphology similar to mature endothelial cells
forming a monolayer with a cobblestone appearance. They express endothelial
markers such as CD31, Von Willebrand factor (vWF), VE-cadherin and
endothelial nitric oxide synthase (eNOS) but do not express myeloid cell markers
(127; 131; 255). They have a high proliferative capacity and readily form tube like
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structures (129; 256). There is concern that these cells may not originate from
the bone marrow and represent shed proliferative endothelial cells (131; 257;
258). However some studies have confirmed their bone marrow origin and their
mobilization from bone marrow in response to stimuli such as exercise, G-CSF,
and VEGF (127; 259; 260). Late outgrowth cells are phylogenetically similar to a
true CAC and a detailed functional characterization of these cells is necessary for
their therapeutic application. Hence, we assessed the angiogenic potential of late
outgrowth cells cultured from subjects with and without diabetes using both in
vitro and in vivo methods.
METHODS AND MATERIALS
Culture of late outgrowth cells from human peripheral blood
Venous peripheral blood was collected in four 6ml EDTA (Vacutainer)
tubes from the cohort described in Chapter II. A total of 20ml of blood was
collected for cell culture, and these samples were processed within 4h of
collection. Plasma was separated by centrifugation at 1500g for 10min. The nonplasma fraction of blood was collected, diluted with 20ml of PBS and layered
atop of 15ml of ficoll (Ficoll-Paque, GE Healthcare) and the tubes centrifuged at
740g for 30min at room temperature. The buffy coat layer was collected and
washed twice with EBM-2 basal medium (Lonza CC-3156) containing 10% fetal
bovine serum (FBS, Atlanta Biologicals), penicillin and streptomycin. Cells were
pelleted by centrifugation at 515g for 10min, and a cell count was performed prior
to the last wash. Cells were resuspended in complete medium [EGM-2 (Lonza
CC-3202) containing 10% FBS] and seeded into 6-well fibronectin coated plates
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(Corning 354402), at a cell concentration between 2-5 x 107 cells in 4ml complete
media. The cells were cultured at 37°C with 5% CO2. Two days after seeding the
media was gently removed, the wells washed once with fresh complete media
and replaced with 3ml of fresh media. Subsequently, media was changed every
day for 5 days, then every other day until the outgrowth cells were ~80%
confluent. Cobblestone-like colonies appeared between 1 – 4 weeks. Upon
confluence,

the

cells

were

detached

with

0.25%

trypsin-EDTA

(Life

Technologies) and replated to scale up in collagen-1 coated plates (BD Labware
354400).
Immunophenotyping of late outgrowth cells
Late outgrowth cells were characterized prior to their use in the tubeforming assays and for injection in the hind limb ischemia experiment. At ~ 80%
confluence, cells were detached from the plate using 0.25% trypsin-EDTA,
neutralized in media and pelleted at 400g for 5min at 4oC. The cells were
resuspended in 100µl of PBS+1% BSA containing 10µl of FcR (Miltenyi Biotec)
block and incubated for 10min. At this time 50 µl aliquots of were left unstained
(negative control) or were incubated with a panel of fluorescently-tagged antihuman monoclonal antibodies [PE-CF594-CD34 (BD Biosciences), APC-AC133
(Miltenyi Biotec), V450-CD31 (BD Biosciences), Alexa Fluor 700-VEGFR2 (R&D
Systems) and V500-CD45 (BD Biosciences)] for 30 min in the dark. In addition a
live-dead green stain (Invitrogen) was used to discriminate cell viability. Then 1ml
of PBS+1% BSA was added and the samples spun by centrifugation at 400g for
5min. The supernatant was discarded and the pellet was reconstituted in 300µl
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PBS+ 1% BSA and a total of 10,000 cells were then analyzed on an LSR II flow
cytometer (Becton Dickinson).
Data analysis was accomplished using FlowJo software. After initially
selecting live cells, we identified cells positive for each of the individual antigens
(CD34, AC133, VEGFR2, CD31 and CD45). From the CD34 gate, cells were
further sorted for CD31 and VEGFR2, and their expression was reported as a
percent of the parent gate.
Tube forming assay
Late outgrowth cells from both diabetics and non-diabetics were cultured
in normal media containing 5mM of glucose. To mimic a sustained hyperglycemic
milieu, cells from diabetics were also cultured in high glucose (25mM). Diabetic
cells were incubated with an equivalent amount of an osmotic control (mannitol).
Cells between passages 3-6 were used for all functional assays.
For the tube formation assay, we chilled the matrigel (BD Biosciences), pipette
tips, and a 96 well plate (Corning) by placing them at -20oC overnight. The next
day, 50µl of matrigel was pipetted into each well while keeping the plate, pipette
tips and matrigel cold. The matrigel-coated plate was then incubated at 37oC for
60min. The cultured EPCs were detached from tissue culture plates with 0.25%
Trypsin-EDTA, washed and counted. Each matrigel well was seeded with 1.2 x
104 cells in 200µl of complete media, and incubated at 37oC. Each sample was
seeded in duplicate. Images were captured at 8, 16 and 24 hours using an EVOS
FL microscope (Thermo Fischer Scientific). Completely formed tubes were
counted from the images using NIH Image-J software.
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Hind limb ischemia and CAC injections
All procedures were performed in accordance with the University of
Louisville’s Institutional Animal Care and Use Committee. Four animal groups
were used: sham with vehicle (PBS) injection, sham with cell injection, hind limb
ischemia (HLI) with vehicle injection, and HLI with cell injection (Figure 15A).
Unilateral hind limb ischemia was induced by ligation of the femoral artery in 12
week old, female SCID-beige mice (C.B-Igh-1b/GbmsTac-Prkdcscid-Lystbg N7;
Taconic). Cells from diabetics or non-diabetic subjects were cultured and
harvested as described above and reconstituted in PBS to contain 0.5 x 106 cells
in 40ul. We then injected 20ul (0.25 x 106 cells) at 2 sites, intramuscular and
medial to the site of femoral artery ligation (Figure 15B). Control mice received
injections of PBS. Anesthesia was induced by isoflurane inhalation (3%
isoflurane mixed with 100% O2) and maintained by continued isoflurane
inhalation at a lower dose (1-2%). The left groin area was shaved and a small
incision made through the skin. The femoral artery and vein exposed, sterile 7.0
sutures were threaded under and around the femoral artery and vein, knotted for
permanent ligation and both blood vessels bisected. Skin was closed using
sterile nylon 6.0 sutures and tissue adhesive sealant. Sham HLI surgery was
conducted in the same manner, except that blood vessels were not ligated. Body
temperature was maintained at 37oC for the procedure.
Supportive care involved antibiotic prophylaxis with Baytril 0.1mg/ml in
drinking water started 1 week prior to surgery and was discontinued on post-op
day 10. Analgesic support was provided with Ketoprofen 5 mg/kg subcutaneous
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(SQ) prior to surgery and at 24 h post-op. Hydration was supported by 1ml of
normal saline SQ prior to surgery and subsequently with Napa-Nector (Systems
Engineering) until post-op day 7. Nutritional supplementation with Diet Gel Boost
(Clear H2O) was provided from post-op day 1 to 7.
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FIGURE 15. Model for the in vivo assessment of the angiogenic potential of
late outgrowth cells. Illustrated is the experimental design for hind limb
ischemia experiment (A), and the anatomy of the femoral artery (B). Depicted in
white are the sites of femoral artery ligation and cell injections.
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FIGURE 15.
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Laser Doppler perfusion imaging
Mice were anesthetized as above and blood flow measurements from both
ischemic and non-ischemic feet and hind limbs were obtained weekly for 4 weeks
using the Laser Doppler Perfusion Imaging scanner (Moor LDI2 Instrument,
Wilmington, DE). LDPI values scale linearly with the product of red blood cell
velocity and the number of blood cells within the tissue, and are listed in arbitrary
units. The images are recorded as digital color-coded images with the red hue
indicating regions with maximum perfusion; yellow indicating medium perfusion
and blue representing the lowest perfusion values (261). Two images were taken
for every mouse, and analyzed for return of blood flow (recovery) to the ischemic
leg as a percentage of blood flow in the non-ischemic leg.

STATISTICS
Categorical data are reported as a frequency and analyzed using chi square or
Fishers exact test. Continuous data are reported as mean ± SEM and,
comparison between groups was analyzed using the non-parametric Mann
Whitney test or ANOVA. Linear regression was used to examine the relationship
between percent CD34+/CD31+ cells and HbA1c levels. P < 0.05 was considered
statistically significant.
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RESULTS
Late outgrowth cells are decreased in diabetics
The initial appearance of a colony was seen in 76 of 105 subjects, and
there was no difference in colony appearance between diabetics and nondiabetics (Figure 16A). However, not all of colonies continued to expand and, at
week 3 outgrowth cells from 57 subjects continued to grow which allowed for
phenotype characterization. The number of diabetics demonstrating late
outgrowth cells was significantly lower than that from non-diabetics (p = 0.03;
Figure 16B). The dual expression of CD34 and CD31 in the outgrowth cells was
quantified as a percent of the parent population of live cells. Based on the
median value (50th percentile), subjects were dichotomized as lying above or
below the 50th percentile. We found that subjects with diabetes mostly belonged
below the 50th percentile group (lower CD34/CD31 expression; Figure 16C).
Linear regression of CD34+/CD31+ expression and HbA1c levels showed a
significant negative correlation (Figure 17).
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FIGURE 16. Chi square analysis of late outgrowth cells from diabetics and
non-diabetics. Illustrated are subjects with and without initial outgrowths (A),
subjects with persistent outgrowth cells at three weeks (B), and outgrowth cells
containing greater or less than the 50th percentile of CD34/CD31 positivity (C).
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FIGURE 16.
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FIGURE 17. Illustrated is the linear regression analysis of percent CD34+/CD31+
in the late outgrowth cells against HbA1c levels (A).

Also illustrated are

representative images of the morphology of late outgrowth cells based on the
percentile of CD34+/CD31+ expression (B).
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FIGURE 17.
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In vitro assessment of angiogenic potential of late outgrowth cells
Late outgrowth cells from diabetics and non-diabetics formed tube-like
structures on matrigel. The morphology of the tube forms among the diabetics
had a greater variability. While some diabetics had small tube forms, others had
open or broken tubes. However, overall there was no difference in the number of
tube forms between the groups (Figure18).
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FIGURE 18. Tube-like structure formation in non-diabetics and diabetics.
Illustrated are the representative images of tube-like structures from individual
subjects (A), and the quantification of these structures (B) reported as mean ±
SEM.
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In vivo assessment of angiogenic potential of late outgrowth cells
Cultured CACs were tested for their ability to enhance revascularization
following acute induction of hind limb ischemia. A murine model of hind limb
ischemia was used and either vehicle or an equal number of cultured cells from
diabetics and non-diabetics were injected.
The recovery of perfusion in the ischemic limb was compared with the
perfusion in the non-surgical limb from the same animal (Figure 19). An equal
proportion of animals from all 4 groups had necrotic toes, and only one animal in
the vehicle treated group had a loss of all toes. These animals were excluded
from the LDPI analysis (Figure 20). An enhanced recovery of perfusion (20 –
35%) was detected in animals that received cells from non-diabetics compared to
animals that received vehicle or cells cultured from diabetics, at weeks 3 and 4
post-ischemia (Figure 21).
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FIGURE 19. Laser Doppler perfusion imaging (LDPI). Four weeks after
induction of ischemia, LDPI images were acquired. Illustrated are representative
images and a graphical representation of percent recovery.
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FIGURE 19.
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FIGURE 20. Foot images. Illustrated are representative images of necrotic toes
in the vehicle and cell treated groups after induction of hind limb ischemia by
ligation of femoral vessels.
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FIGURE 20.

PBS$

DM$

NDM$

PBS$

DM$

NDM$

PBS$

DM$

NDM$

118

FIGURE 21. Line graph of perfusion recovery. Illustrated is the calculated
percent recovery of perfusion 4 weeks after HLI.
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FIGURE 21.
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Morphology and immunophenotyping of late outgrowth cells.
Cultured cells from all non-diabetic patients had a uniform cobblestone
morphology. The outgrowth cells from diabetics were heterogeneous, and
included a mixture of cobblestone cells and spindle shaped cells. In these cells
we quantified the expression of CD34, CD31, KDR, CD34+/CD31+ and
CD34+/KDR+ (Figure 22). The expression of AC133 and CD45 was also
measured and found to be less than 1% (data not shown). A comparative
analysis of the antigens expressed on cells from non-diabetics and diabetics
demonstrated that cells from diabetics had a decreased expression of CD31 and
CD34+/CD31+ (Figure 23).
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FIGURE 22. Morphology and immunophenotyping of late outgrowth cells.
Illustrated are representative cells from non-diabetics (A), and diabetics (B). The
numericals on the images are subject ID numbers. Tabulated below the images
are quantifications of the expression of surface antigens from the outgrowth cells
for each subject.
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FIGURE 22.
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FIGURE 23. Surface antigen expression. Cells from diabetic (DM) and nondiabetic (NDM) subjects were analyzed for the expression of CD31, CD34+ and
KDR by flow cytometry and a percent positive for various population determined.
CD31 expression is decreased in diabetics compared to non-diabetics.
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FIGURE 23.
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DISCUSSION
In this study we investigated the differences in angiogenic potential of
culture-expanded CACs from non-diabetics and diabetics. We found that
diabetics were less likely to have late outgrowth cells from peripheral blood
mononuclear cells, than non-diabetics, and suggesting decreased adhesive and
proliferative capacities of CACs in diabetics. Similar impairments in the function
of cultured CACs are reported from subjects with both T1D and T2D (149; 262).
Furthermore we found that the phenotype of outgrowth cells differed, wherein the
percentage of CD34+/CD31+ cells was decreased in diabetics. Finally we found a
negative correlation between HbA1c levels and the percentage of CD34+/CD31+
cells in the outgrowth, suggesting that hyperglycemia alters the properties of late
outgrowth cells that may contribute to endothelial dysfunction and poor collateral
vessel formation in diabetics.
The in vitro assessment of angiogenic potential by formation of tube-like
structures was analyzed in both normoglycemic and hyperglycemic conditions.
Tube formation was no different between diabetics and non-diabetics regardless
of glucose levels in the media. This could be a result of selection bias where only
the diabetics that had cells capable of angiogenesis had outgrowths, or that if
supported by exogenous growth factors as contained in matrigel, diabetic
outgrowth cells are capable of making tube forms. Evidence that hyperglycemia
impairs CAC function in vitro is unclear Schatteman et al, reported results similar
to ours where supplementing the culture media with high glucose did not impair
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CAC proliferation and differentiation, while Ingram et al reported reduced tube
like structure formation when neonatal endothelial colony-forming cell were
cultured in hyperglycemia (153; 263). Late outgrowth cells are also reported to
have decreased migration, proliferation, secretion of angiogenic growth factors,
and increased apoptosis when cultured in hyperglycemia or in the presence of
AGEs (264; 265). The mechanisms by which hyperglycemia affects the function
of mature endothelial cells has been studied extensively and potentially similar
pathways may affect hyperglycemia-induced CAC dysfunction. Krankel et al
demonstrated decreased proliferation, and survival of cultured CACs due to
reduced NO production, and Seeger et al demonstrated decreased survival of
CACs due to hyperglycemia induced activation of the p38 MAP-kinase pathway
(266; 267).
Next we assessed the in vivo angiogenic potential of diabetic and nondiabetic late outgrowth cells in a murine model of hind limb ischemia. We show
that outgrowth cells from non-diabetics enhanced revascularization by 25 - 30%
when compared to diabetic outgrowth cells and vehicle, suggesting that diabetic
cells had a decreased ability to enhance collateral vessel growth. Improved
revascularization using ex vivo expanded early and late outgrowth cells from
healthy donors is also reported by other investigators in animal models of hind
limb ischemia and myocardial ischemia, (46; 78; 128; 153; 268). Some of these
studies have reported the incorporation CACs into capillaries, while others have
reported a paracrine effect with the secretion of growth factors enabling further
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recruitment of CACs or differentiation of local cells as possible mechanisms for
this effect.
Reduced post-ischemic revascularization in diabetic animals, and a
reduced

ability

of

outgrowth

cells

from

diabetic

animals

to

improve

revascularization in healthy mice have also been reported (269-271). These
studies report decreased mobilization, migration, adhesiveness, proliferation and
increased apoptosis of CACs as mechanisms for reduced vascularization.
A clinical trial using intramuscular injection of autologous CACs to treat
critical limb ischemia due to peripheral arterial disease, The Therapeutic
Angiogenesis using Cell Transplantation (TACT) trial, reported significantly
improved leg pain, reduced ulcer size, and pain-free walking distance that were
maintained for at least 2 years (156), and significantly lowered amputation rates
in the in the treatment group in the 3 year follow up (157). Similar positive
outcomes were reported in a randomized study investigating the effects of
intracoronary infusion of CACs, The Transplantation of Progenitor Cells and
Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI) trial,
that has now published a five year follow up report (158-160). Improvements in
cardiac function included reduced functional infarct size, improvement of LV
ejection fraction, reduced diagnosis of heart failure and no hospitalization for
heart failure.
It is speculated that autologous stem cell therapy in diabetics may not
improve vascular function unless CAC dysfunction associated with diabetes is
mitigated and/or CACs are made resistant to the diabetic environment. Animal
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studies using genetically modified CACs such as cells that over-express VEGF,
eNOS, and telomerase reverse transcriptase have been tested in models of
ischemia and have enhanced revascularization (154; 272; 273).

Human

mesenchymal stem cells transduced with the pro-survival gene Akt-1 also
showed enhanced viability and greater functional repair in a mouse infarct model
(155). However at this time reports of clinical trials that specifically evaluate
autologous angiogenic stem cell therapy in diabetics are yet to be published.
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CHAPTER V
CONCLUDING DISCUSSION

This project was designed to obtain new understanding of vascular
pathobiology with particular attention to the role of circulating stem cells as key
determinants of CVD risk and vascular dysfunction in T2D. Through the course of
this project the following questions were addressed: 1) Are circulating CACs
depleted in T2D? 2) What specific phenotypes are depleted? 3) Do
hyperglycemia, insulin resistance, inflammation, and oxidative stress play a role
in this depletion? 4) Are CACs counts decreased in early endothelial
dysfunction? 5) What mechanisms contribute to CAC depletion? 6) Does the
angiogenic potential of CACs from T2D subjects differ from non-diabetic
subjects?
These questions were addressed in a cohort of 105 subjects recruited
from the Endocrinology and Primary Care Clinics of the University of Louisville.
The cohort comprised of a relatively young adults with a mean age of 48 years
who were mostly obese and with high prevalence of hypertension, diabetes and
hyperlipidemia. The average duration of diabetes reported was 10 years. None of
the subjects in the study were acutely ill, they did not received transfusions of
any blood products in the past year, and were not hospitalized in the past 5
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months. Among the 47 diabetics the prevalence of vasculopathy was as follows:
16 subjects were diagnosed with micro-vasculopathy only, 17 subjects with both
micro- and macro-vasculopathy, 2 subjects with only macro-vasculopathy, and
12 subjects did not have the diagnosis of vasculopathy.
To assess the depletion of CACs in diabetes we used an approach that
differed from previous work, i.e., instead of comparing CAC counts from diabetics
and non-diabetics, two groups that have many differences and are essentially
non-comparable, we stratified CAC counts into high and low levels and then
analyzed for the predilection of subjects with diabetes in either group. We found
that diabetics had greater representation in the low cell count group, which
affirmed that CACs are depleted in subjects with T2D. Our analysis was
extensive and included 18 phenotypes of CACs based on the inclusion and
exclusion of stem cell antigens (CD34, AC133), endothelial antigens (CD31,
VEGFR2), and leukocyte antigens (CD45, CD14). We found seven phenotypes
to be depleted in diabetics: (CD34+, CD34+/KDR+, CD34+/31+, AC133+,
AC133+/CD31+, CD45+/AC133+/CD34+, and CD34+/AC133+/CD31+/CD45dim).
We continued our analysis using one phenotype, CAC-3, that meets the
most comprehensive definition of an early CAC. We found that depletion of CAC3 in diabetes was associated with hyperglycemia (HbA1c) but not insulin
resistance, inflammation (hsCRP) or oxidative stress (isoprostane F2 metabolite).
All of which are known to contribute to diabetic vasculopathy, The selective
association of hyperglycemia among the other variables measured may suggest
that hyperglycemia is the antecedent event and that maintaining euglycemia
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could delay the onset or progression of vasculopathy by CAC mediated vascular
regeneration. This delineation was possible as our cohort contained subjects with
and without vasculopathy, and the average duration of diabetes was about a
decade.
We also found that CAC-3 counts had a positive correlation with reactive
hyperemia, a measure of endothelial function. This finding suggests that the
levels of CAC-3 may be an important biomarker or a physiological correlate of
endothelial injury, dysfunction or inability to regenerate. This association, if
confirmed in larger clinical studies, may allow for bedside assessment of the
reparative capacity of the vasculature and may have prognostic value in
instituting preventive care measures to improve endothelial health in T2D
patients.
Additional studies provided further evidence for the role of hyperglycemia
in mediating CAC-3 depletion. Specifically we found a negative association of
HbA1c levels with VEGFR2 expression on CAC-3, which suggests decreased
survival and proliferation of CAC-3. Further, we also found decreased expression
of the homing receptor CXCR4 on CAC-3 in diabetics, which may further impede
repair and regeneration of the vasculature in diabetes.
As an indicator of mitochondrial activity we measured ΔΨ and found that it
was no different in the diabetics and non-diabetics in CAC-3. Measures of
oxidative stress (isoprostane F2 metabolite) in our cohort did not affect CAC-3
levels but did have a negative association with VEGFR2 expression on CAC-3. It

132

is possible that effects of oxidative stress will be more evident in older subjects
and in subjects with diabetes of longer duration.
Hyperglycemia was also found to have a positive association with plasma
sICAM-1 and sE-selectin levels, suggesting that hyperglycemia leads to
activation of inflammatory pathways and endothelial activation. While the
biological functions of soluble adhesion molecules in plasma are not clearly
understood, it has been suggested that they could decrease the adhesion of
circulating cells to the activated endothelium and modulate cell trafficking across
the endothelium. It is also suggested they could bind to circulating cells and
deliver a stimulus (274). Our finding that sICAM-1 levels bear a negative
association with CAC-3 counts suggests that it may play a role in CAC survival.
Further in vitro and in vivo studies are needed to understand the mechanisms
that underlie this association. It has been reported by Ridker et al that high
sICAM-1 levels predict myocardial infarction, while Werner et al reported that low
CAC counts predicted mortality in CAD patients. Our finding of the negative
association of CAC-3 and sICAM-1 levels reinforces that the biologic function of
sICAM-1 needs to be investigated further (246; 275).
The results presented in Chapter 4 wherein we found decreased ability to
culture late outgrowth cells from diabetics support the finding in Chapter 2 that
CACs are depleted in diabetes. In addition this result suggests that diabetes is
associated with a decrease in the adhesive and proliferative capacities of CACs.
We also found that despite similar culture conditions, outgrowths from diabetics
had a greater variability in their phenotype and surface antigen expression. The
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in vitro assessment of CAC function by tube formation in matrigel was no
different in the non-diabetic and diabetic outgrowth cells. However the in vivo
assessment of angiogenic potential showed that outgrowth cells from diabetics
did not enhance revascularization and were no different from vehicle. This
suggests that when supplied with external growth factors as in matrigel, these
cells are capable of tube-like structure formation, however in and ischemic
environment the cells fail to support revascularization, suggesting deficiencies in
paracrine function or differentiation.
Overall this project supports the observation that diabetes results in CAC
depletion. It further suggests that the depletion of CAC-3 is associated with poor
long-term glycemic control and endothelial dysfunction. We report that both
diabetes and endothelial dysfunction contribute to the depletion of CACs
independently. The positive association of reactive hyperemia and CAC-3 may
reduce the bench-to-bedside gap in assessing endothelial function and the
reparative capacity of the vasculature. This project also adds to our knowledge of
the possible mechanisms by which diabetes induces vascular injury and
dysfunction. However because of the cross-sectional design of the study, we
were unable to establish cause-effect relationships between diabetes and CAC
dysfunction. Further investments in understanding CAC biology, and in
methodologies that identify early vascular dysfunction could lead to the institution
of preventive care measures or therapeutics directed to improving the number
and function of CACs that could improve CVD outcomes, and reduce the burden
of CVD in subjects with diabetes.
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